<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Valproate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Valproate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Valproate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10035" href="/d/html/10035.html" rel="external">see "Valproate: Drug information"</a> and <a class="drug drug_patient" data-topicid="11136" href="/d/html/11136.html" rel="external">see "Valproate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708868"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hepatic failure resulting in fatalities has occurred in patients receiving valproate. These incidents usually have occurred during the first 6 months of treatment. Serious or fatal hepatotoxicity may be preceded by nonspecific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a loss of seizure control may also occur. Patients should be monitored closely for appearance of these symptoms. Serum liver tests should be performed prior to therapy and at frequent intervals thereafter, especially during the first 6 months.</p>
<p style="text-indent:-2em;margin-left:2em;">Children &lt;2 years of age are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple antiseizure medications, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. When these products are used in this patient group, they should be used with extreme caution and as a sole agent. The benefits of therapy should be weighed against the risks. The incidence of fatal hepatotoxicity decreases considerably in progressively older patient groups.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Patients with mitochondrial disease:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">There is an increased risk of valproate-induced acute liver failure and resultant deaths in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA polymerase gamma (POLG) gene (eg, Alpers-Huttenlocher syndrome). Valproate is contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children younger than 2 years who are clinically suspected of having a mitochondrial disorder. In patients &gt;2 years of age who are clinically suspected of having a hereditary mitochondrial disease, only use after other antiseizure medications have failed. This older group of patients should be closely monitored during treatment with valproate for the development of acute liver injury with regular clinical assessments and serum liver testing. POLG mutation screening should be performed in accordance with current clinical practice.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fetal risk:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Valproate can cause major congenital malformations, particularly neural tube defects (eg, spina bifida). In addition, valproate can cause decreased IQ scores and neurodevelopmental disorders following in utero exposure. Valproate is therefore contraindicated for prophylaxis of migraine headaches in pregnant women and in women of childbearing potential who are not using effective contraception. Valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. In such situations, effective contraception should be used.</p>
<p style="text-indent:-2em;margin-left:2em;">A Medication Guide describing the risks of valproate is available for patients.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pancreatitis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of life-threatening pancreatitis have been reported in both children and adults receiving valproate. Some of the cases have been described as hemorrhagic with a rapid progression from initial symptoms to death. Cases have been reported shortly after initial use as well as after several years of use. Patients and guardians should be warned that abdominal pain, nausea, vomiting, and/or anorexia can be symptoms of pancreatitis that require prompt medical evaluation. If pancreatitis is diagnosed, valproate should ordinarily be discontinued. Alternative treatment for the underlying medical condition should be initiated as clinically indicated.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F233020"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Depakote;</li>
<li>Depakote ER;</li>
<li>Depakote Sprinkles</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868558"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Divalproex;</li>
<li>APO-Valproic Acid;</li>
<li>Depakene;</li>
<li>Epival;</li>
<li>JAMP-Valproic Acid;</li>
<li>MYLAN-Divalproex;</li>
<li>PMS-Valproic;</li>
<li>PMS-Valproic Acid;</li>
<li>TEVA-Divalproex [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1055961"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiseizure Agent, Miscellaneous</span>;</li>
<li>
<span class="list-set-name">Infantile Spasms, Treatment</span></li></ul></div>
<div class="block don drugH1Div" id="F53462616"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b> Due to the increased risk of valproic acid and derivatives-associated hepatotoxicity, valproic acid and derivatives are not preferred agents for use in neonates and not routinely used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24524454','lexi-content-ref-28558955','lexi-content-ref-27581850']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24524454','lexi-content-ref-28558955','lexi-content-ref-27581850'])">Ref</a></span>); reserve use in refractory cases only after other multiple therapeutic options have failed.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee0c61b7-1ce6-4bea-9e0c-1ed373a1c6be">Refractory seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Refractory seizures:</b> Limited data available: Oral: Loading dose: 20 mg/kg, followed by a maintenance dose of 5 to 10 mg/kg/dose every 12 hours; adjust dose according to serum concentrations; dosing based on a report of six neonates (GA: 30 to 41 weeks) that showed oral valproic acid effectively controlled seizure activity in five of six patients; however, therapy was discontinued in 50% of the patients due to hyperammonemia; frequent monitoring is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9536846','lexi-content-ref-3126410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9536846','lexi-content-ref-3126410'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="996bce23-9994-43d2-8fde-0ce9cce87c3c">Refractory status epilepticus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Refractory status epilepticus:</b> Limited data available: IV: Loading dose: 20 to 40 mg/kg followed by a continuous IV infusion of 5 mg/kg/<b>hour</b> was used in five neonates; once patients were seizure-free for 12 hours and no longer had seizure activity on EEG, the infusion rate was decreased every 2 hours by 1 mg/kg/<b>hour</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10851397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10851397'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F233045"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Use of Depakote ER in pediatric patients &lt;10 years of age is not recommended; do not confuse Depakote ER with Depakote. <b>Erroneous substitution of Depakote (delayed-release tablets) for Depakote ER has resulted in toxicities; only Depakote ER is intended for once daily administration.</b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a88a9dbf-8161-4267-8b85-a53eda1346a9">Migraine, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Divalproex sodium (eg, Depakote tablets):</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥5 years and Adolescents ≤16 years: Limited data available: Oral: Initial 10 to 15 mg/kg/day in 2 divided doses; maximum initial dose: 250 mg/dose. Titrate as needed over 4 to 6 weeks to 40 to 45 mg/kg/day in 2 divided doses; maximum daily dose: 1,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15623677','lexi-content-ref-16120482','lexi-content-ref-10971664','lexi-content-ref-18174091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15623677','lexi-content-ref-16120482','lexi-content-ref-10971664','lexi-content-ref-18174091'])">Ref</a></span>). Dosing based on multiple pediatric trials. In one open-label trial of divalproex sodium (DVS) (n=42; age range: 7 to 16 years); dose was initiated at 15 mg/kg/day in 2 divided doses and increased as needed over 6 weeks to 45 mg/kg/day in 2 divided doses. After 4 months, 78.5% of subjects had a 50% decrease in headaches frequency, 14.2% had a 75% decrease in headache frequency, and 9.5% became headache free (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10971664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10971664'])">Ref</a></span>). In a randomized comparative trial of pediatric patients aged 4 to 15 years, sodium valproate (n=54) was initiated at 10 mg/kg/day in 2 divided doses and titrated based on clinical response and tolerability up to a maximum dose of 40 mg/kg/day in divided doses; similar efficacy to propranolol (n=56) was observed with regards to decrease in headache frequency by &gt;50%, mean headache duration, headache severity, and improved response to rescue medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16120482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16120482'])">Ref</a></span>). A small (n=10) open-label trial of pediatric patients 9 to 17 years showed a statistically significant decrease in mean frequency of headache attacks, severity, and duration with divalproex sodium therapy using a daily dose range of 500 to 1,000 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12390647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12390647'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥17 years: Depakote: Oral: 250 mg twice daily; adjust dose based on patient response; maximum daily dose: 1,000 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Depakote ER: Limited data available: Children ≥12 years and Adolescents: Oral: 500 mg once daily for 15 days, may increase to 1,000 mg once daily; adjust dose based on patient response; usual dosage range: 250 to 1,000 mg/day; dose should be individualized; if smaller dosage adjustments are needed, use Depakote delayed-release tablets; results from a Phase 3, long-term (12 months) open-label trial of 241 patients (age: 12 to 17 years) showed a 75% decrease in median 4-week headache days between the first and fourth months of the trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19040679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19040679'])">Ref</a></span>). In a short-term (12 weeks), double-blind, randomized placebo-controlled trial of 304 patients (age: 12 to 17 years), Depakote ER (250 to 1,000 mg/day) was no different than placebo at reducing the 4-week headache rate; however, a large placebo effect was observed in the study population (Apostol 2008).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e6773ec9-0f41-4277-9d18-baeab511ae5f">Migraine, treatment; refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, treatment; refractory:</b> Limited data available, efficacy results variable, optimal regimen not established:</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV: Adolescents 500 or 1,000 mg infused at 50 mg/minute; a repeat dose of 500 mg may be administered if pain relief not observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15985107','lexi-content-ref-25986331']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15985107','lexi-content-ref-25986331'])">Ref</a></span>); dosing based on two retrospective reports that evaluated experience in 43 patients treated for acute migraine attack(s) (n=60; some subjects presented with multiple attacks); the mean age in both reports was 15 years and the majority of patients received 1,000 mg doses. One trial evaluated 48 clinic visits for acute migraine attack in 31 patients; adequate pain relief was reported in 77.6% of visits (n=45) after a single valproic acid dose; the mean time to achieve maximum pain relief was 63 ± 31 minutes (range: 15 to 160 minutes) after a single dose of valproic acid; maximum pain reduction following a repeat 500 mg dose was observed at 124 ± 62 minutes (range: 20 to 250 minutes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15985107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15985107'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Children ≥4 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Loading dose:</i> IV: 20 mg/kg; maximum dose: 2,000 mg/dose infused over 30 to 60 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous infusion: </i>IV: Initial: 1 mg/kg/<b>hour</b>; adjust to maintain target serum concentrations of 80 to 100 mcg/mL (assessed at 2 to 4 hours and at 24 hours after loading dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26715390','lexi-content-ref-17381378','lexi-content-ref-29494433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26715390','lexi-content-ref-17381378','lexi-content-ref-29494433'])">Ref</a></span>). Dosing based on a retrospective report including 83 patients (mean age: 12.9 years; range: 4 to 18 years) who received IV valproate for status migrainosus after failing home oral therapy and initial IV therapy in the emergency department (diphenhydramine, metoclopramide, and ketorolac); the mean reported rate was 1 mg/kg/<b>hour</b>, and an excellent response (100% pain reduction) was reported in 55 (66.3%) patients; within the responder group, 56% reported response within 16 hours and 76% within 24 hours. Patients were then transitioned to oral valproic acid therapy migraine prophylaxis therapy on the delayed-released formulation initiated at the same dosage as last 24 hours of IV infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29494433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29494433'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33243222-cb08-4d46-b4f8-2d9c8a772e74">Seizure disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizure disorder:</b>
<b>Note:</b> Due to the increased risk of valproic acid and derivatives-associated hepatotoxicity in patients &lt;2 years, valproic acid and derivatives are not preferred agents in this population.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>General dosing (including focal onset seizures with impaired consciousness or awareness [complex partial seizures], mixed seizure disorders, tonic-clonic):</i> Children and Adolescents: Limited data available for some seizure types and ages &lt;10 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-PinaGarza.2013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-PinaGarza.2013'])">Ref</a></span>): Initial: 10 to 15 mg/kg/day in 1 to 3 divided doses; increase by 5 to 10 mg/kg/day at weekly intervals until seizures are controlled or side effects preclude further increases; daily doses &gt;250 mg should be given in divided doses; maintenance: 30 to 60 mg/kg/day in 2 to 3 divided doses; Depakote and Depakote Sprinkle can be given twice daily; <b>Note:</b> Children receiving more than 1 antiseizure medication (ie, polytherapy) may require doses up to 100 mg/kg/day in 3 to 4 divided doses.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Generalized nonmotor (absence) seizures, focal onset seizures with or without impaired consciousness or awareness (simple and complex):</i> Children and Adolescents: Initial: 15 mg/kg/day in 1 to 3 divided doses; increase by 5 to 10 mg/kg/day at weekly intervals until seizures are controlled or side effects preclude further increases; daily doses &gt;250 mg should be given in divided doses; maintenance: 30 to 60 mg/kg/day in 2 to 3 divided doses; Depakote and Depakote Sprinkle can be given twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Conversion to Depakote ER from a stable dose of immediate release or delayed release: </i>May require an increase in the total daily dose between 8% and 20% administered once daily to maintain similar serum concentrations (Kernitsky 2005; manufacturer's labeling). For doses that do not directly convert to a Depakote ER dose form, clinicians may consider increasing to the next highest dose of the immediate or delayed-release (eg, Depakote) formulation before converting to the appropriate daily dose of Depakote ER.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Conversion to monotherapy from adjunctive therapy:</i> The concomitant antiseizure drug (AED) can be decreased by ~25% every 2 weeks. This reduction may be started at initiation of valproic acid therapy or delayed by 1 to 2 weeks if there is a concern that seizures are likely to occur with a reduction. The speed and duration of withdrawal of the concomitant AED can be highly variable, and patients should be monitored closely during this period for increased seizure frequency.</p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral: Children and Adolescents: Limited data available in some cases depending on seizure types and age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-PinaGarza.2013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-PinaGarza.2013'])">Ref</a></span>): IV: Total daily IV dose is equivalent to the total daily oral dose; however, IV dose should be divided with a frequency of every 6 hours; if IV form is administered 2 to 3 times/day, close monitoring of trough concentrations is recommended; switch patients to oral product as soon as clinically possible as IV use &gt;14 days has not been studied.</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: Limited data available: Children and Adolescents: Dilute oral syrup 1:1 with water for use as a retention enema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3334021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3334021'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: 17 to 20 mg/kg once.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: 10 to 15 mg/kg/dose every 8 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c28d3f0d-8bbe-4432-9488-5e76cde2e5ec">Status epilepticus; urgent therapy/second-line therapy or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus; urgent therapy/second-line therapy or refractory:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose: Initial:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>American Epilepsy Society guidelines</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382'])">Ref</a></span>): Infants, Children, and Adolescents: IV: 40 mg/kg as a single dose; maximum dose: 3,000 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Neurocritical care guidelines </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>): Infants, Children, and Adolescents: IV: 20 to 40 mg/kg; may be followed by an additional 20 mg/kg after 10 minutes if needed.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance dose: Continuous IV infusion: 5 mg/kg/<b>hour</b> after the loading dose was used in pediatric continuous IV infusion studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17940245','lexi-content-ref-10851397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17940245','lexi-content-ref-10851397'])">Ref</a></span>); once patients were seizure-free for 6 hours, the infusion rate was decreased by 1 mg/kg/<b>hour</b> every 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17940245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17940245'])">Ref</a></span>). Lower initial infusion rates of 1 mg/kg/<b>hour</b> have also been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22326977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22326977'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51193228"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;margin-left:0em;display:inline">All patients: Mild to severe impairment: No dosage adjustment required (including patients on hemodialysis); however, protein binding is reduced in patients with renal impairment; monitoring <b>only</b> total valproate serum concentrations may be misleading.</p></div>
<div class="block dohp drugH1Div" id="F51193229"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">All patients:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: Not recommended for use in hepatic disease; clearance is decreased with liver impairment. Hepatic disease is also associated with decreased albumin concentrations and 2- to 2.6-fold increase in the unbound fraction of valproate. Free concentrations of valproate may be elevated while total concentrations appear normal; therefore, monitoring <b>only</b> total valproate concentrations may be misleading.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is contraindicated.</p></div>
<div class="block doa drugH1Div" id="F233025"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10035" href="/d/html/10035.html" rel="external">see "Valproate: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>All doses in this monograph are expressed as the equivalent amounts of valproic acid. Available formulations of valproate (active moiety) include valproic acid, valproate sodium, and divalproex sodium (also known as valproate semisodium) salts. The dosing recommendations are expressed as the total daily dose (ie, per 24 hours) unless stated otherwise. The total daily oral dose is given in 1 to 4 divided doses per day depending on the type of preparation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Although the manufacturer recommends divided doses of the DR formulation (usually dosed 2 to 3 times daily) to maintain stable serum concentrations, once the dose is stabilized, once-daily dosing may be tolerated in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17960970','lexi-content-ref-6766529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17960970','lexi-content-ref-6766529'])">Ref</a></span>). However, fluctuating serum concentrations may increase the risk for breakthrough seizures in patients with seizure disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23190215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23190215'])">Ref</a></span>). The ER oral formulation is not available in Canada.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1969751f-c027-4072-874e-d4df29195cbe">Bipolar disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute mania or acute episodes with mixed features (in combination with or as an alternative to an antipsychotic) (BAP [Goodwin 2016]):</b></p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dose: <b>Oral:</b> Initial: 500 to 750 mg/day in 1 to 4 divided doses based on chosen formulation (immediate release usually dosed 3 to 4 times daily, delayed release usually dosed 2 to 3 times daily, extended release commonly dosed once daily but may also be dosed twice daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26979387','lexi-content-ref-17696575','lexi-content-ref-6766529','lexi-content-ref-19014751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26979387','lexi-content-ref-17696575','lexi-content-ref-6766529','lexi-content-ref-19014751'])">Ref</a></span>); increase by 250 to 500 mg every 1 to 3 days to reach desired clinical effect and therapeutic serum concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26979387','lexi-content-ref-Stovall.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26979387','lexi-content-ref-Stovall.2018'])">Ref</a></span>); therapeutic serum levels generally occur with doses of 1.5 to 2.5 <b>g/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stovall.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stovall.2018'])">Ref</a></span>). Maximum recommended dosage: 60 <b>mg/kg/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-based loading dose <i>for rapid symptom control</i>: <b>Oral:</b> Initial: 20 to 30 mg/kg/day in 1 to 4 divided doses based on chosen formulation (immediate release usually dosed 3 to 4 times daily, delayed release usually dosed 2 to 3 times daily, extended release commonly dosed once daily but may also be dosed twice daily). After 2 to 3 days, adjust dose upward or downward to reach desired clinical effect and therapeutic serum concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26979387','lexi-content-ref-17696575','lexi-content-ref-20101186','lexi-content-ref-17107240','lexi-content-ref-10665626','lexi-content-ref-6766529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26979387','lexi-content-ref-17696575','lexi-content-ref-20101186','lexi-content-ref-17107240','lexi-content-ref-10665626','lexi-content-ref-6766529'])">Ref</a></span>); therapeutic serum levels generally occur with doses of 1.5 to 2.5 <b>g/day</b>. To avoid intolerable adverse effects, some experts limit the initial rapid loading dose to 20 mg/kg/day (up to 2 <b>g/day</b> if body weight exceeds 100 kg) and then adjust based on response and serum concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stovall.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stovall.2018'])">Ref</a></span>). Maximum recommended dosage: 60 <b>mg/kg/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Bipolar disorder, depressive episode (alternative agent) (mono- or adjunctive therapy) (off-label use): </b>Based on limited data: <b>Oral:</b> Initial: 500 to 750 mg/day in 1 to 4 divided doses based on chosen formulation (immediate release usually dosed 3 to 4 times daily, delayed release usually dosed 2 to 3 times daily, extended release commonly dosed once daily but may also be dosed twice daily); increase by 250 to 500 mg every 1 to 3 days to reach desired clinical effect and therapeutic serum concentration; therapeutic serum levels generally occur with doses of 1.5 to 2.5 <b>g/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17696575','lexi-content-ref-29536616','lexi-content-ref-15780695','lexi-content-ref-18162014','lexi-content-ref-6766529','lexi-content-ref-20816041','lexi-content-ref-Shelton.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17696575','lexi-content-ref-29536616','lexi-content-ref-15780695','lexi-content-ref-18162014','lexi-content-ref-6766529','lexi-content-ref-20816041','lexi-content-ref-Shelton.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance treatment of bipolar disorder (off-label):</b>
<b>Oral:</b> Continue dose and combination regimen that was used to achieve control of the acute episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12784116','lexi-content-ref-17888516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12784116','lexi-content-ref-17888516'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="67e732c4-b7e3-4abd-be74-0e133a5b58d8">Focal onset seizures and generalized onset seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Focal (partial) onset seizures and generalized onset seizures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> FDA-approved for mono- and adjunctive therapy of complex partial and absence seizures, and adjunctive therapy for multiple seizure types; used off label as monotherapy for other seizure types.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV (non-status epilepticus):</b> Initial monotherapy or adjunctive therapy: 10 to 15 mg/kg/day for complex partial seizures or 15 mg/kg/day for absence seizures in 1 to 4 divided doses based on chosen formulation (<b>Oral:</b> immediate release usually dosed 3 to 4 times daily, delayed release usually dosed 2 to 3 times daily, extended release commonly dosed once daily but may also be dosed twice daily; <b>IV:</b> dosed every 6 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17696575','lexi-content-ref-6766529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17696575','lexi-content-ref-6766529'])">Ref</a></span>). Increase by 5 to 10 mg/kg/day at weekly intervals until optimal clinical response and/or therapeutic levels are achieved; maximum recommended dose: 60 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).<b> Note:</b> Some experts suggest checking serum level ~1 to 2 weeks after initial dose to guide dose adjustments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schachter.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schachter.2023'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Conversion to monotherapy from valproate adjunctive therapy:</i> Initial oral/IV dosage as above. Dosage reduction of the concomitant antiseizure drug may begin when valproate therapy is initiated or 1 to 2 weeks following valproate initiation. Concomitant antiseizure drug withdrawal may be variable, one suggested strategy is tapering the concomitant antiseizure drug over 8 weeks (eg, by ~25% every 2 weeks).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9e9cd0b4-97a8-432f-81f8-7ae9d3a79338">Migraine, intractable and status migrainosus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, intractable and status migrainosus (alternative agent) (off-label use): IV:</b> 500 mg to 1 <b>g</b> as a single dose as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11903525','lexi-content-ref-24523483','lexi-content-ref-26252587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11903525','lexi-content-ref-24523483','lexi-content-ref-26252587'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="683d5204-2f9a-4f90-86f2-dc2acc899423">Migraine, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prevention: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>An adequate trial for assessment of effect is considered to be at least 2 to 3 months at a therapeutic dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31113373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31113373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 500 mg once daily (ER) or in 2 divided doses (DR or ER); increase dose gradually based on response and tolerability in increments of 250 mg/day at intervals &gt;3 days, up to 1 <b>g/day</b> in 1 to 2 divided doses based on chosen formulation (DR or ER). Based on clinical experience, some patients require doses up to 1.5 <b>g/day</b> for sufficient response; however, adverse effects are increased (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9137847','lexi-content-ref-23797677','lexi-content-ref-20159899','lexi-content-ref-Schwedt.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9137847','lexi-content-ref-23797677','lexi-content-ref-20159899','lexi-content-ref-Schwedt.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98f720da-4e7e-4163-a85a-e8df3fee1f21">Status epilepticus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus </b>
<b>(off-label use):</b>
<b>Note: </b> Given in combination with an IV benzodiazepine: <b>IV:</b> Loading dose: 20 to 40 mg/kg administered at a rate up to 10 mg/kg/minute (maximum dose: 3 <b>g</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274','lexi-content-ref-26900382','lexi-content-ref-17319914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274','lexi-content-ref-26900382','lexi-content-ref-17319914'])">Ref</a></span>). In non-convulsive status epilepticus, some experts recommend a maximal infusion rate of 5 mg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Jirsch.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Jirsch.2020'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation of therapy: </b>In patients receiving valproic acid chronically, unless safety concerns require a more rapid withdrawal, valproic acid should be withdrawn gradually (eg, over 2 to 6 months to minimize the potential of increased seizure frequency (in patients with epilepsy) or other withdrawal symptoms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1673736','lexi-content-ref-Sirven.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1673736','lexi-content-ref-Sirven.2023'])">Ref</a></span>). In patients discontinuing therapy for treatment of bipolar disorder, close monitoring for several weeks to months for reemergence of mania/hypomania is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Post.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Post.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosing conversions: Note:</b> The ER formulation is not available in Canada:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Conversion from immediate release to DR or ER</b></i>
<b>:</b> When converting to DR, use the same total daily dose as the immediate release and divide into 2 to 3 daily doses. When converting from immediate release to ER, increase the total daily dose of ER by 8% to 20% and dose once daily (most common) or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17696575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17696575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Conversion from </i></b>
<b>
<i>DR to ER:</i></b> For patients on a stable dose of DR, increase the total daily dose of ER by 8% to 20% to maintain similar serum concentrations, and dose once daily (most common) or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17696575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17696575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Conversion to IV valproate preparations</i></b>
<i>: </i>To continue therapy IV in patients temporarily unable to receive oral therapy, total daily IV dose should be equivalent to the total daily oral dose (expressed as valproic acid) and divided every 6 hours. Trough levels may fall below the equivalent oral regimen when administered less frequently than every 6 hours; in these cases, closely monitor trough plasma concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991078"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: IV, Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥10 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: No specific dosage adjustment necessary; however, free valproate clearance may be reduced up to ~30%. Closely monitor clinical response and tolerability in addition to valproic acid serum concentrations, when appropriate. Monitoring of free valproic acid concentrations (when available) is preferred due to decreased protein binding in severe kidney impairment. Total valproate concentrations may be misleading (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> No specific dosage adjustment necessary. At therapeutic concentrations, dialysis decreases valproic acid concentrations by 20% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); supplemental doses are typically unnecessary as concentrations rebound within a few hours after dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16970741','lexi-content-ref-2118241']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16970741','lexi-content-ref-2118241'])">Ref</a></span>). Closely monitor clinical response and tolerability in addition to valproic acid serum concentrations, when appropriate; monitoring of free valproic acid concentrations (when available) is preferred due to decreased protein binding in severe kidney impairment. Total valproate concentrations may be misleading (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Minimally dialyzed (~4.5%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6407847']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6407847'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> No specific dosage adjustment necessary. Closely monitor clinical response and tolerability in addition to valproic acid serum concentrations, when appropriate; monitoring of free valproic acid concentrations (when available) is preferred due to decreased protein binding in severe kidney impairment. Total valproate concentrations may be misleading (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> No specific dose adjustment necessary. However, critically ill patients receiving CRRT may exhibit reduced protein binding and increased free valproic acid concentrations, leading to increased removal. Closely monitor clinical response and tolerability in addition to valproic acid serum concentrations, when appropriate; monitoring of free valproic acid concentrations (when available) is preferred. Total valproate concentrations may be misleading (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21325101','lexi-content-ref-27587068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21325101','lexi-content-ref-27587068'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral: </b>No specific dose adjustment necessary. However, critically ill patients receiving PIRRT may exhibit reduced protein binding and increased free valproic acid concentrations, leading to increased removal. Closely monitor clinical response and tolerability in addition to valproic acid serum concentrations, when appropriate; monitoring of free valproic acid concentrations (when available) is preferred. Total valproate concentrations may be misleading (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988359"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Mild to moderate impairment: Not recommended for use in hepatic disease; clearance is decreased with liver impairment. Hepatic disease is also associated with decreased albumin concentrations and 2- to 2.6-fold increase in the unbound fraction. Free concentrations of valproate may be elevated while total concentrations appear normal, therefore, monitoring only total valproate concentrations may be misleading.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Severe impairment: Use is contraindicated.</p></div>
<div class="block arsc drugH1Div" id="F55060876"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Valproate may cause CNS effects, mostly related to CNS depression (including <b>dizziness </b>and<b> drowsiness</b>). However, nervous system stimulation (eg, <b>nervousness, insomnia</b>, <b>tremor</b>) may also occur at a high frequency in some patients. More severe reactions, including <b>delirium </b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19836623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19836623'])">Ref</a></span>) and <b>hallucinations</b> have also been reported. <b>Parkinsonism</b> and <b>cognitive dysfunction</b> are also concerns associated with several antiseizure medications, including valproate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31721077','lexi-content-ref-31421858']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31721077','lexi-content-ref-31421858'])">Ref</a></span>). Cognitive decline has particularly been a concern in patients with bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25261261','lexi-content-ref-31421858']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25261261','lexi-content-ref-31421858'])">Ref</a></span>). In general, valproate appears to have less effect on cognitive abilities compared to other older antiseizure medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8783377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8783377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; decreases neuronal excitation in the CNS by enhancing the activity of gamma-amino butyric acid (GABA). Valproate also has a direct effect on voltage gated sodium channels, may regulate the excitatory activity of NMDA glutamate receptors, and regulates neuronal gene expression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29260458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29260458'])">Ref</a></span>). Of note, cognitive function does not appear to correspond with ammonia levels in patients receiving valproate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31276904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31276904'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; with respect to common (dose-related) CNS effects, the onset and duration correlate with the increase in concentration. Identification of patients with Parkinsonism and cognitive decline have been described after several years of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16453247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16453247'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Increased unbound valproate concentrations (decreased albumin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29621091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29621091'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of multiple antiseizure medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26033949','lexi-content-ref-32006792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26033949','lexi-content-ref-32006792'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Valproate is associated with a range of hematologic effects. Coagulopathy including <b>thrombocytopenia</b>, <b>decreased platelet aggregation</b>, and acquired von Willebrand disease type I may result in <b>hemorrhage</b> in patients receiving valproate. Severe complications including <b>hemorrhagic stroke</b> have occurred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29260458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29260458'])">Ref</a></span>). In some cases, platelet counts may normalize with continued treatment. Thrombocytopenia is generally reversible with dose reduction or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18031547']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18031547'])">Ref</a></span>). Other blood disorders including <b>aplastic anemia</b>, <b>neutropenia</b>, and <b>pure red cell aplasia</b> have been reported infrequently (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10695824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10695824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; thrombocytopenia may result from direct bone marrow toxicity, increased platelet destruction, or antibody-mediated depletion of thrombocytes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29260458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29260458'])">Ref</a></span>). Valproate may inhibit erythroid differentiation and may activate the myelo-monocytic pathway (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24619070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24619070'])">Ref</a></span>). Direct suppression of bone marrow by an idiosyncratic mechanism is responsible for the most severe reactions (eg, aplastic anemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10695824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10695824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; thrombocytopenia may occur between 8 days to 16 months after initiation. In one study, the mean time to onset was 82 days (range: 38 to 170 days); may develop more quickly depending on dose/valproate levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18031547']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18031547'])">Ref</a></span>). Neutropenia may occur in the first few weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24619070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24619070'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Thrombocytopenia corresponds to:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29260458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29260458'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher dosage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29260458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29260458'])">Ref</a></span>). Probability of thrombocytopenia increases with total valproate levels ≥110 mcg/mL in females or ≥135 mcg/mL in males.</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29260458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29260458'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity/hepatic failure</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Valproate is associated with <b>hepatotoxicity</b> and <b>hepatic failure</b>, including fatal cases in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929376','lexi-content-ref-21167499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929376','lexi-content-ref-21167499'])">Ref</a></span>). May progress despite discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; idiosyncratic. Drug-mediated hepatotoxicity can be the result of direct toxicity/hepatocyte necrosis or the formation of a neoantigen, which results in an immunologic reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18341684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18341684'])">Ref</a></span>). Direct hepatotoxic reactions may be caused by reactive valproate metabolites, inhibition of fatty acid β-oxidation, excessive oxidative stress, and a susceptibility to these effects may be encoded by genetic variants of key enzymes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30931853','lexi-content-ref-32117699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30931853','lexi-content-ref-32117699'])">Ref</a></span>). Valproate can cause significant mitochondrial toxicity which may underlie many of these events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28732239','lexi-content-ref-30873497','lexi-content-ref-15858222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28732239','lexi-content-ref-30873497','lexi-content-ref-15858222'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied. In patients with defined susceptibility mutations, including mitochondrial DNA polymerase gamma (POLG), hepatotoxicity commonly occurs within the first 3 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31799506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31799506'])">Ref</a></span>). The manufacturer’s labeling notes the onset of hepatotoxicity is most common in the first 6 months of therapy; however, clinicians should note these effects may occur at any time during therapy. Idiosyncratic drug-induced liver injury tends to occur with a more delayed onset (weeks to months) as complex mechanisms, including adaptive immune responses, have been implicated in these reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31307585']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31307585'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Pediatric patients; neonates, infants, and children &lt;2 years of age are at higher risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30931853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30931853'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Hereditary mutations of the POLG gene (eg, Alpers-Huttenlocher syndrome [AHS]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30931853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30931853'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Neurologic disorders</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Seizure disorder accompanied by developmental delay (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30931853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30931853'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Metabolic disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30931853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30931853'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Patients on multiple antiseizure medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30931853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30931853'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Genetic variants of some enzymes, such as carbamoyl phosphate synthetase (CPS1), glutathione S-transferase (GST), superoxide dismutase-2 (SOD2), UDP-glucuronosyl transferase (UGT), and cytochrome P450 isoenzymes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30931853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30931853'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperammonemia and encephalopathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperammonemia</b> and/or <b>hyperammonemic</b>
<b>encephalopathy</b> have been reported following the initiation of valproate therapy. This may be characterized by drowsiness, lethargy, changes in level of consciousness, slowing of cognition, vomiting, and focal neurological deficits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16774619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16774619'])">Ref</a></span>). Several types of hyperammonemia and encephalopathy have been suggested to occur, based on whether they occur in the presence or absence of hepatic dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16787750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16787750'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related; idiosyncratic. In the presence of risk factors (eg, urea cycle disorders, deficiency of carnitine, or high concentrations), valproate metabolism is shunted to a greater proportion of metabolism by omega-oxidation leading to the formation of 4-en-valproic acid, which decreases the function of carbamoyl-phosphate synthetase-1, a critical step in the urea cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16774619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16774619'])">Ref</a></span>). Valproate therapy may induce carnitine deficiency in some individuals, particularly in children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19280426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19280426'])">Ref</a></span>). Valproate may also decrease the formation of N-acetyl-glutamic acid which is an allosteric activator of carbamoyl-phosphate synthetase 1 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21147182']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21147182'])">Ref</a></span>). Ammonia accumulation leads to glutamine and swelling of astrocytes with associated cerebral edema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16774619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16774619'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; may generally occur in the first week of therapy in patients with susceptibility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31980035']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31980035'])">Ref</a></span>). However, in some cases the first detection of encephalopathy has occurred after several years of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28411969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28411969'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent therapy with antipsychotic drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25192484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25192484'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent therapy with liver enzyme-inducing antiseizure medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25192484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25192484'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent therapy with topiramate (even in patients who previously tolerated monotherapy)</p>
<p style="text-indent:-2em;margin-left:6em;">• Nutritional status or a deficiency of carnitine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26336183']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26336183'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Overdose or higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25192484','lexi-content-ref-24868521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25192484','lexi-content-ref-24868521'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Sex (inconsistent data; some studies have shown a higher risk in males whereas others have shown a higher risk in females) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25192484','lexi-content-ref-23409971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25192484','lexi-content-ref-23409971'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Valproate is associated with several forms of delayed hypersensitivity including <b>toxic epidermal necrolysis</b> (TEN), <b>Stevens-Johnson syndrome</b> (SJS), and <b>drug reaction with eosinophilia and systemic symptoms</b> (DRESS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32117699','lexi-content-ref-10612272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32117699','lexi-content-ref-10612272'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related; immunologic<b>. </b>Severe cutaneous reactions, including SJS/TEN and DRESS, are delayed type IV hypersensitivity reactions involving a T-cell mediated drug-specific immune response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; type IV reactions are delayed hypersensitivity reactions that typically occur days to weeks after drug exposure, but may occur more rapidly (usually within 1 to 4 days) upon re-exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014'])">Ref</a></span>). <b>
<i></i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent therapy with lamotrigine may increase the risk of SJS/TEN and DRESS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18986457','lexi-content-ref-30809807','lexi-content-ref-29204346']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18986457','lexi-content-ref-30809807','lexi-content-ref-29204346'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous hypersensitivity to aromatic antiseizure medications: Cross-reactivity of valproate, a non-aromatic antiseizure medication, with aromatic antiseizure medications (eg, phenytoin and carbamazepine), is not well described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18986457','lexi-content-ref-22116946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18986457','lexi-content-ref-22116946'])">Ref</a></span>). However, there are isolated reports of patients who develop DRESS following an aromatic antiseizure medications, as well as with valproate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20354855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20354855'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pancreatitis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of <b>pancreatitis</b> have been reported in both children and adults receiving valproate. Some of the cases have been described as hemorrhagic pancreatitis with rapid progression from initial symptoms to death. Recurrence after rechallenge with valproate has also been documented (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12423394','lexi-content-ref-17015559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12423394','lexi-content-ref-17015559'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related; idiosyncratic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12423394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12423394'])">Ref</a></span>). Direct toxicity has been proposed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8403815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8403815'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; in clinical trials, pancreatitis that was possibly or probably related to valproate occurred between 48 and 88 days after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12423394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12423394'])">Ref</a></span>). In postmarketing reports, cases occurred in the first year of therapy, but cases have been reported beyond 1 year. In one series, the average onset was 32 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17015559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17015559'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Most cases have been reported in children with epilepsy or in adults with kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31783774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31783774'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal ideation/tendencies</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antiseizure medications have been associated with <b>suicidal ideation</b> and <b>suicidal tendencies</b>. However, the FDA meta-analysis has been criticized due to several important limitations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19496806','lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19496806','lexi-content-ref-22994856'])">Ref</a></span>). The risk of suicide is increased in epilepsy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19453718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19453718'])">Ref</a></span>), but the occurrence of suicidal ideation/tendencies in epilepsy is multifactorial. While some AEDs (but not all) have been associated with treatment-emergent psychiatric effects such as anxiety and depression, other factors such as postictal suicidal behavior and pertinent patient history must also be evaluated to provide an accurate assessment of risk for any individual drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22994856'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; peak incidence of suicidality across AEDs (not specific to individual agents) has been noted to occur between 1 and 12 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28190254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28190254'])">Ref</a></span>). A review of clinical trials noted that risk extended from 1 week to 24 weeks of therapy, corresponding to the duration of most trials.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>History of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20818889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20818889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Use in conditions other than epilepsy, depression, or bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20818889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20818889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>In patients with bipolar disorder, risk for repeat suicide attempt was increased in patients with alcohol/substance abuse disorder, rapid cycling, and earlier age at onset of first manic episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28190254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28190254'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F232982"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported with oral administration, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (6% to 24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (oral: 7% to 23%; IV: 1%), anorexia (4% to 12%), diarrhea (oral: 7% to 23%; IV: &lt;1%), dyspepsia (7% to 23%), nausea (oral: 15% to 48%; IV: 3% to 6%), vomiting (oral: 7% to 27%; IV: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (1% to 27%; dose related)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (12% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (oral: 12% to 25%; IV: 5% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 1</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, drowsiness (oral: 7% to 30%; IV: 2% to 11%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 2</a>)</span><span class="table-link" style="display:none;">Drowsiness</span>, headache (oral: 31%; IV: 3% to 4%), insomnia (9% to 15%), nervousness (oral: 7% to 11%; IV: &lt;1%), pain (oral: 11%; IV: 1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Valproic Acid and Derivatives: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Valproic Acid and Derivatives)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Valproic Acid and Derivatives)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Acute mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">89</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">97</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Acute mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">338</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">263</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complex partial seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">77</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">70</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral (high dose)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complex partial seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">131</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral (low dose)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complex partial seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">134</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Valproic Acid and Derivatives: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Valproic Acid and Derivatives)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Valproic Acid and Derivatives)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Acute mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">338</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">263</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Acute mania</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">89</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">97</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">30%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral (high dose)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complex partial seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">131</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complex partial seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">77</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">70</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral (low dose)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complex partial seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">134</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">202</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">81</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">115</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (oral: 6% to 27%; IV: 7%), tremor (oral: 9% to 57%; IV: &lt;1%)<span class="lexi-table-link-container"> (<a aria-label="Tremor table link" class="lexi-table-link" data-table-id="lexi-content-tremor" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tremor')">table 3</a>)</span><span class="table-link" style="display:none;">Tremor</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tremor" frame="border" id="lexi-content-tremor" rules="all">
<caption style="text-align:center;">
<b>Valproic Acid and Derivatives: Adverse Reaction: Tremor</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Valproic Acid and Derivatives)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Valproic Acid and Derivatives)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">57%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral (high dose)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complex partial seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">131</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complex partial seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">77</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">70</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral (low dose)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complex partial seizures</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">134</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Migraine</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">202</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">81</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia (16%), visual disturbance (amblyopia, blurred vision: 4% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (6% to 11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (&gt;1%), chest pain (2%), edema (1% to 5%), facial edema (1% to 5%), hypertension (1% to 5%), hypotension (1% to 5%), orthostatic hypotension (1% to 5%), palpitations (1% to 5%), peripheral edema (3% to 8%), tachycardia (1% to 5%), vasodilation (oral: 1% to 5%; IV: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (oral: &gt;1%; IV: &lt;1%), ecchymoses (1% to 5%), erythema nodosum (&gt;1%), furunculosis (1% to 5%), maculopapular rash (1% to 5%), pruritus (1% to 5%), seborrhea (1% to 5%), skin rash (6%), vesiculobullous dermatitis (&gt;1%), xeroderma (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea (1% to 5%), weight gain (4% to 9%), weight loss (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (1% to 5%), dysgeusia (2%), dysphagia (&gt;1%), eructation (1% to 5%), fecal incontinence (1% to 5%), flatulence (1% to 5%), gastroenteritis (1% to 5%), gingival hemorrhage (&gt;1%), glossitis (1% to 5%), hematemesis (1% to 5%), hiccups (&gt;1%), increased appetite (6%), oral mucosa ulcer (&gt;1%), pancreatitis (1% to 5%; may be hemorrhagic pancreatitis) (Ozaydin 2008; Werlin 2006), periodontal abscess (1% to 5%), stomatitis (1% to 5%), xerostomia (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (1% to 5%), dysmenorrhea (1% to 5%), dysuria (1% to 5%), urinary frequency (1% to 5%), urinary incontinence (1% to 5%), urinary tract infection (&gt;1%), vaginal hemorrhage (1% to 5%), vaginitis (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (&gt;1%), hypoproteinemia (&gt;1%), leukopenia (&gt;1%), petechia (1% to 5%), prolonged bleeding time (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (1% to 5%), increased serum aspartate aminotransferase (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection (&gt;1%), viral infection (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (IV: 2%), pain at injection site (IV: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (1% to 5%), abnormal gait (1% to 5%), abnormality in thinking (6%), agitation (1% to 5%), amnesia (4% to 7%), anxiety (1% to 5%), ataxia (8%), catatonia (1% to 5%), chills (1% to 5%), confusion (1% to 5%), depression (1% to 5%), dysarthria (1% to 5%), emotional lability (6%), hallucination (1% to 5%), hyperreflexia (1% to 5%), hypertonia (1% to 5%), malaise (1% to 5%), myasthenia (1% to 5%), paresthesia (oral, IV: ≤7%), personality disorder (1% to 5%), psychosis (&gt;1%), sleep disorder (&gt;1%), speech disturbance (1% to 5%), tardive dyskinesia (1% to 5%), twitching (1% to 5%), vertigo (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (1% to 5%), back pain (8%), discoid lupus erythematosus (1% to 5%), hypokinesia (1% to 5%), lower limb cramp (1% to 5%), myalgia (1% to 5%), neck pain (1% to 5%), neck stiffness (1% to 5%), osteoarthritis (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (1% to 5%), dry eye syndrome (1% to 5%), eye pain (1% to 5%), nystagmus disorder (1% to 8%), photophobia (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness (1% to 5%), otitis media (1% to 5%), tinnitus (1% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (5%), cough (1% to 5%), dyspnea (1% to 5%), epistaxis (1% to 5%), pharyngitis (oral: 2% to 8%; IV: &lt;1%), pneumonia (1% to 5%), rhinitis (1% to 5%), sinusitis (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1% (any indication):</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Inflammation at injection site (IV)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Euphoria (IV), hypoesthesia (IV)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (any indication or formulation): Nervous system: Suicidal ideation, suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any indication or formulation):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, hemorrhagic stroke (Buoli 2018), hypersensitivity angiitis (Lasic 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Changes of hair (color, texture) (Kakunje 2018), erythema multiforme (Gau 2008), erythroderma (Rener-Primec 2014), nail bed changes (Güler 2017), nail disease (Solak 2017), psoriasiform eruption (Kwan 2014), skin photosensitivity, Stevens-Johnson syndrome (Gau 2008; Hashim 2004), toxic epidermal necrolysis (Gau 2008; Hashim 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Abnormal thyroid function test (Connacher 1987), acute intermittent porphyria (Herrick 1989), decreased plasma carnitine concentrations (Al-sharefi 2015), female hyperandrogenism (Morrell 2008), galactorrhea not associated with childbirth, hirsutism (Sidhu 2018), hyperammonemia (elevations identified in up to 50% of patients, but asymptomatic in most) (Segura-Bruna 2006), hyperammonemic encephalopathy (up to 2.5% of patients, particularly high risk in patients with urea cycle disorders) (Lewis 2017), hyperglycinemia, hyponatremia (Yamamoto 2019), increased testosterone level (DeVries 2007; Sidhu 2018), infrequent uterine bleeding (Joffe 2006), SIADH (Bavbek 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Parotid gland enlargement (Derin 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Asthenospermia (Yerby 1999), azoospermia, breast hypertrophy, decreased ejaculate volume, Fanconi-like syndrome (risk increased in children or in adults who cannot walk, require tube-feeding, and/or have a developmental delay) (Knights 2016; Ono 2019), irregular menses, male infertility (Yerby 1999), oligospermia (Ocek 2018), polycystic ovary syndrome (may be more common in females with bipolar disorder) (Okanovvic 2016; Rasgon 2005), spermatozoa disorder (abnormal morphology) (Yerby 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acquired blood coagulation disorder (coagulation factor deficiencies, von Willebrand’s disease), agranulocytosis, aplastic anemia, bone marrow depression, decreased platelet aggregation, hypofibrinogenemia, lymphocytosis, macrocytosis (with or without anemia), neutropenia (Acharya 2000), pancytopenia, pure red cell aplasia (Acharya 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (Mindikoglu 2011), hepatotoxicity (Chalasani 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction (Bota 2011, Toker 2015), multi-organ hypersensitivity reaction (Conilleau 1999, Dreesman 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Gupta 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, behavioral changes (including apathy, behavioral deterioration, and irritability), cerebral atrophy (reversible or irreversible), cognitive dysfunction (Pigoni 2020), delirium (Gareri 2009; may manifest as acute encephalopathy in the absence of elevated ammonia levels), dementia (some cases reversible) (Papazian 1995), developmental delay (learning disorder), disturbance in attention, emotional disturbance, hostility, hypothermia, parkinsonism (Balzabal-CarvaLLo 2019), psychomotor agitation, Reye's syndrome (specifically Reye's-like syndrome) (Hilmas 2000, Sugimoto 1983), seizure (Tsuyusaki 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (Vestergaard 2004), decreased bone mineral density (Fan 2019), osteopenia, osteoporosis (effect on fracture risk inconsistent/controversial; however, multiple biochemical changes documented) (Pitetzis 2017; Verrotti 2010), ostealgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Acute angle-closure glaucoma (associated with DRESS) (Sanoria 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss (Yeap 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Pulmonary: Interstitial pneumonitis (Kim 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis (Yoshikawa 2002)</p></div>
<div class="block coi drugH1Div" id="F232998"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to valproic acid, divalproex, derivatives, or any component of the formulation; hepatic disease or significant impairment; urea cycle disorders; prevention of migraine in pregnant women and women of childbearing potential who are not using effective contraception; known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG; eg, Alpers-Huttenlocher syndrome [AHS]) or children &lt;2 years of age suspected of having a POLG-related disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Treatment of epilepsy in pregnant women, unless no suitable alternative; treatment of epilepsy in women of childbearing potential, unless requirements of Pregnancy Prevention Program fulfilled (see Canadian labeling for more information); known systemic primary carnitine deficiency with uncorrected hypocarnitinemia; known porphyria.</p>
<p style="text-indent:-2em;margin-left:4em;">Epival: Additional contraindication: Treatment of bipolar disorder in pregnant women, unless no suitable alternative; treatment of bipolar disorder in women of childbearing potential, unless requirements of Pregnancy Prevention Program fulfilled (see Canadian labeling for more information).</p></div>
<div class="block war drugH1Div" id="F232979"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute head trauma: Not recommended for post-traumatic seizure prophylaxis in patients with acute head trauma; study results for this indication suggested increased mortality with IV valproate sodium use compared to IV phenytoin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dementia: Not recommended for treatment of dementia-associated agitation or aggression; evidence suggests lack of efficacy for this indication, as well as an increased risk of adverse effects (Baillon 2018; NICE 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution as older adults may be more sensitive to sedating effects and dehydration; in some older adult patients with somnolence, concomitant decreases in nutritional intake and weight loss were observed. Reduce initial dosages in older adult patients and closely monitor fluid status, nutritional intake, somnolence, and other adverse events.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal: Medication residue in stool has been reported (rarely) with oral divalproex sodium formulations; some reports have occurred in patients with shortened GI transit times (eg, diarrhea) or anatomic GI disorders (eg, ileostomy, colostomy). In patients reporting medication residue in stool, it is recommended to monitor valproate level and clinical condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Viral replication: In vitro studies have suggested valproate stimulates the replication of HIV and CMV viruses under experimental conditions. The clinical consequence of this is unknown but should be considered when monitoring affected patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Antiseizure medications should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878665"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Although carnitine is indicated for the management of valproic acid overdose and hepatotoxicity (and strongly recommended for select patients at high risk of valproic acid-associated hepatotoxicity), the role of routine prophylactic carnitine supplementation is unclear (Freeman 1994; Raskind 2000). A case of a fatal hepatotoxic reaction has been reported in a child receiving valproic acid despite carnitine supplementation (Murphy 1993).</p>
<p style="text-indent:0em;margin-top:2em;">Medication residue in stool has been reported (rarely) with oral Depakote (divalproex sodium) formulations; some reports have occurred in patients with shortened GI transit times (eg, diarrhea) or anatomic GI disorders (eg, ileostomy, colostomy). In patients reporting medication residue in stool, it is recommended to monitor valproate level and clinical condition.</p></div>
<div class="block dosfc drugH1Div" id="F22782778"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Strengths of divalproex sodium and valproate sodium products are expressed in terms of valproic acid</p></div>
<div class="block foc drugH1Div" id="F232991"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, Immediate Release, as valproic acid: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release Sprinkle, Oral, as divalproex sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depakote Sprinkles: 125 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, Immediate Release, as valproate sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg/5 mL (5 mL, 10 mL, 473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as valproate sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral, as divalproex sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depakote: 125 mg [contains corn starch, fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depakote: 125 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depakote: 250 mg [contains corn starch, fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depakote: 250 mg [DSC] [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depakote: 500 mg [contains corn starch, fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depakote: 500 mg [DSC] [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg, 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as divalproex sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depakote ER: 250 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depakote ER: 250 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depakote ER: 500 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depakote ER: 500 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F232975"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16570489"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (Stavzor Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (100): $153.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (100): $301.09</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (100): $555.19</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, sprinkles</b> (Depakote Sprinkles Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (100): $137.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, sprinkles</b> (Divalproex Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (100): $89.61</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Depakene Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (100): $404.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Valproic Acid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (100): $82.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Depacon Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (5 mL): $25.76</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Valproate Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (5 mL): $8.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Syrup</b> (Depakene Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/5 mL (480 mL): $413.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Depakote ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (100): $257.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (100): $453.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Divalproex Sodium ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (100): $167.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (100): $295.36</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Depakote Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (100): $144.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (100): $283.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (100): $522.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Divalproex Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (100): $89.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (100): $176.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (100): $324.97</p></div>
<div class="block dinfoc drugH1Div" id="F52868559"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, Immediate Release, as valproic acid: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral, as valproic acid: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, Immediate Release, as valproate sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depakene: 250 mg/5 mL (240 mL, 480 mL) [contains fd&amp;c red #40 (allura red ac dye), methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg/5 mL (450 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral, as divalproex sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Epival: 125 mg [contains corn starch, fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Epival: 250 mg [contains corn starch, fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Epival: 500 mg [contains corn starch, fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 125 mg, 250 mg, 500 mg</p></div>
<div class="block admp drugH1Div" id="F52613995"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer with food to decrease adverse GI effects; do not administer with carbonated drinks.</p>
<p style="text-indent:-2em;margin-left:4em;">Depakote ER: Swallow whole; do not crush or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Depakote sprinkle capsules: May be swallowed whole or capsule may be opened and sprinkled on small amount (1 teaspoonful) of soft food (eg, pudding, applesauce) to be used immediately; do not crush or chew sprinkle beads; do not store drug food mixture for later use.</p>
<p style="text-indent:-2em;margin-left:4em;">Depakene capsule: Swallow whole; do not break, crush, or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Migraine, acute therapy:</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent IV doses: Adolescents: In trials, doses were infused at 50 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15985107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15985107'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV (including loading doses): Children ≥4 and Adolescents: In trials, loading dosing were infused over 30 to 60 minutes followed by a continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26715390','lexi-content-ref-17381378','lexi-content-ref-29494433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26715390','lexi-content-ref-17381378','lexi-content-ref-29494433'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Status epilepticus:</p>
<p style="text-indent:-2em;margin-left:6em;">Manufacturer recommendations: Dilute dose prior to administration; infuse over 60 minutes; maximum infusion rate: 20 mg/minute; <b>Note:</b> Rapid infusions may be associated with an increase in adverse effects; infusions of ≤15 mg/kg administered over 5 to 10 minutes (1.5 to 3 mg/<b>kg</b>/minute) were generally well tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12536052']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12536052'])">Ref</a></span>). In pediatric patients, an infusion rate of 1.5 to 3 mg/kg/minute has been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Rapid IV loading doses: Infants and Children: Dilute dose prior to administration; administer at 1.5 to 3 mg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274','lexi-content-ref-12752474']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274','lexi-content-ref-12752474'])">Ref</a></span>). Faster infusion rates have been used in some studies; doses of 20 to 40 mg/kg have been administered over 1 to 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17940245','lexi-content-ref-10851397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17940245','lexi-content-ref-10851397'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal: Dilute oral solution or syrup prior to rectal administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3334021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3334021'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F232995"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Oral valproate products may cause GI upset; taking with food or slowly increasing the dose may decrease GI upset should it occur.</p>
<p style="text-indent:-2em;margin-left:4em;">Divalproex sodium tablets (delayed release, extended release, and enteric coated [Canadian product]) and valproic acid capsules (immediate release): Swallow whole; do not crush or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Divalproex sodium delayed release sprinkle capsules: May be swallowed whole or capsule opened and sprinkled on small amount (1 teaspoonful) of soft food (eg, pudding, applesauce) to be used immediately (do not store or chew).</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Tablet, extended and delayed release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Delayed-release and extended-release tablets should be swallowed whole. Do not crush or chew. Immediate-release capsule formulation is available but should not be chewed or crushed. Sprinkle capsules, oral solution, and injectable formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, close clinical monitoring is advised in the immediate postoperative phase for the theoretical circumstance of reduced absorption after bariatric surgery. Conversion to oral solution should be considered for high-risk labeled and off-label clinical indications (ie, seizure, mania, agitation).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For IV use only.</p>
<p style="text-indent:-2em;margin-left:4em;">Seizures (non-status epilepticus): Following dilution to final concentration, manufacturer's labeling recommends administering over 60 minutes at a rate ≤20 mg/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Status epilepticus: Loading dose: Infuse at 3 to 6 mg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>); however, evidence suggest rates of 10 mg/kg/minute may be safely used with doses up to 30 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17319914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17319914'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49133423"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F233013"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Oral capsules:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: Store at 15°C to 25°C (59°F to 77°F).</p>
<p style="text-indent:-2em;margin-left:4em;">Delayed release: Store at 25°C (77° F); excursions are permitted between 15°C and 30°C (59°F and 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral sprinkle capsules: Delayed release: Store below 25°C (77°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Immediate release: Store below 30°C (86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral tablets:</p>
<p style="text-indent:-2em;margin-left:4em;">Delayed release: Store below 30°C (86°F).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Store tablets at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release [Canadian product]: Store at 15°C and 25°C (59°F and 77°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Store at controlled room temperature 15°C to 30°C (59°F to 86°F). Stable in D5W, NS, and LR for at least 24 hours when stored in glass or PVC.</p></div>
<div class="block meg drugH1Div" id="F16335927"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Depakene, Depakote, Depakote ER: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021168s044lbl.pdf%23page%3D48&amp;token=GuTOJ9E%2FlACoqWm7FUv1xnWqA%2BW40myhAh4WjAljg39DYEXqd9LJBjpAIOvA9LGLudvbQ0eL18wgQdGNBto8TQIM7%2BafdnNJF1MsJoLN0N6uxK8%2BrqXROe5jyK5rdJpP&amp;TOPIC_ID=12873" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021168s044lbl.pdf#page=48</a></p></div>
<div class="block usep drugH1Div" id="F53569403"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release capsules and syrup (Depakene): Monotherapy and adjunctive therapy in the treatment of patients with focal onset seizures with impaired consciousness or awareness (complex partial seizures) (FDA approved in ages ≥10 years and adults), monotherapy and adjunctive therapy of generalized typical and atypical nonmotor seizures (simple and complex absence seizures) (FDA approved in pediatric patients [age not specified] and adults), and adjunctive therapy in patients with multiple seizure types (FDA approved in pediatric patients [age not specified] and adults); has also been used to treat mixed seizure types, myoclonic, and generalized tonic-clonic (grand mal) seizures; may be effective in infantile spasms; oral syrup has also been used rectally for treatment of seizure disorders when oral route is not available</p>
<p style="text-indent:-2em;margin-left:4em;">Delayed-release tablets (Depakote): Monotherapy and adjunctive therapy in the treatment of patients with focal onset seizures with impaired consciousness or awareness (complex partial seizures) (FDA approved in ages ≥10 years and adults), monotherapy and adjunctive therapy of generalized typical and atypical nonmotor seizures (simple and complex absence seizures), and adjunctive therapy in patients with multiple seizure types (FDA approved in pediatric patients [age not specified] and adults); prophylaxis of migraine headaches (FDA approved in ages ≥17 years and adults); treatment of manic episodes of bipolar disorders (FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release tablets (Depakote ER): Monotherapy and adjunctive therapy in the treatment of patients with focal onset seizures with impaired consciousness or awareness (complex partial seizures), monotherapy and adjunctive therapy of generalized typical and atypical nonmotor seizures (simple and complex absence seizures), and adjunctive therapy in patients with multiple seizure types (All epilepsy types listed: FDA approved in ages ≥10 years and adults); prophylaxis of migraine headaches (FDA approved in adults); treatment of manic episodes of bipolar disorders (FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Sprinkle capsules (Depakote): Monotherapy and adjunctive therapy in the treatment of patients with focal onset seizures with impaired consciousness or awareness (complex partial seizures) (FDA approved in ages ≥10 years and adults); monotherapy and adjunctive therapy of generalized typical and atypical nonmotor seizures (simple and complex absence seizures), and adjunctive therapy in patients with multiple seizure types (FDA approved in pediatric patients [age not specified] and adults); has also been used to treat mixed seizure types, myoclonic, and generalized tonic-clonic (grand mal) seizures; may be effective in infantile spasms</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Injection (Depacon): Monotherapy and adjunctive therapy in the treatment of patients with focal onset seizures with impaired consciousness or awareness (complex partial seizures) (FDA approved in ages ≥10 years and adults), monotherapy and adjunctive therapy of focal seizures with awareness or impaired awareness (simple and complex absence seizures), and adjunctive therapy in patients with multiple seizure types (FDA approved in pediatric patients [age not specified] and adults); has also been used to treat mixed seizure types, myoclonic, and generalized tonic-clonic (grand mal) seizures; may be effective in infantile spasms. <b>Note:</b> Parenteral formulation is indicated for patients in whom oral administration of valproic acid or derivatives is temporarily not feasible; has also been used in patients with nonconvulsive absence status epilepticus.</p></div>
<div class="block mst drugH1Div" id="F233076"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Depakene may be confused with Depakote</p>
<p style="text-indent:-2em;margin-left:4em;">Depakote may be confused with Depakene, Depakote ER, Senokot</p>
<p style="text-indent:-2em;margin-left:4em;">Depakote ER may be confused with divalproex enteric coated</p>
<p style="text-indent:-2em;margin-left:4em;">Valproate sodium may be confused with vecuronium</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Valproic acid and derivatives, when used in pediatric patients &lt;6 years of age, are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided in infants and used with caution in children &lt;6 years of age due to risk of pancreatitis and fatal hepatotoxicity (strong recommendation; high quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F233062"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2E1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F15578418"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Valproate Products may diminish the therapeutic effect of Apixaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: Valproate Products may increase the serum concentration of Barbiturates. Barbiturates may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine: Valproate Products may enhance the adverse/toxic effect of BUPivacaine. Specifically, the risk of methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabidiol: Valproate Products may enhance the hepatotoxic effect of Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: Valproate Products may increase serum concentrations of the active metabolite(s) of CarBAMazepine. Parent carbamazepine concentrations may be increased, decreased, or unchanged. CarBAMazepine may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbapenems: May decrease the serum concentration of Valproate Products. Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: May increase the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholestyramine Resin: May decrease the serum concentration of Valproic Acid and Derivatives. Management: Separate administration of valproic acid and cholestyramine by at least 3 hours whenever possible in order to minimize this interaction. The impact of concurrent cholestyramine on delayed- or extended-release valproic acid is uncertain.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: Valproate Products may enhance the CNS depressant effect of CloBAZam. CloBAZam may increase the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Valproate Products may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for myocarditis, neutropenia, or CNS toxicities may be increased. Valproate Products may decrease serum concentrations of the active metabolite(s) of CloZAPine. Valproate Products may increase the serum concentration of CloZAPine. Valproate Products may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: May enhance the hepatotoxic effect of Valproate Products. Management: Avoid concomitant use of Synacthen Depot (dosage form available in Canada) with valproic acid.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Valproate Products may diminish the therapeutic effect of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Valproate Products may decrease the serum concentration of Dolutegravir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethosuximide: May decrease the serum concentration of Valproate Products. Valproate Products may increase the serum concentration of Ethosuximide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felbamate: May increase the serum concentration of Valproate Products. Management: Initiate felbamate at typical doses (1,200 mg/day in 3 or 4 divided doses for adults and children 14 years of age or older; 15 mg/kg/day in 3 or 4 divided doses in children 2 to 14 years of age) while reducing the valproate product dose by 20%.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May enhance the adverse/toxic effect of Valproate Products. Specifically, the risk of hepatotoxicity or hyperammonemia may be increased. Valproate Products may decrease the protein binding of Fosphenytoin-Phenytoin. This appears to lead to an initial increase in the percentage of unbound (free) phenytoin and to a decrease in total phenytoin concentrations.  Whether concentrations of free phenytoin are increased is unclear. With long-term concurrent use, total phenytoin concentrations may increase. Fosphenytoin-Phenytoin may decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fotemustine: Valproate Products may enhance the adverse/toxic effect of Fotemustine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ginkgo Biloba: May decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: May increase the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibuprofen: May decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: Valproate Products may enhance the adverse/toxic effect of LamoTRIgine. Valproate Products may increase the serum concentration of LamoTRIgine.  Management: Lamotrigine dose reductions are needed when combined with valproate. See full interaction monograph for details. Increase monitoring for lamotrigine toxicity (eg, rash, hematologic toxicities) when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">LevETIRAcetam: May enhance the CNS depressant effect of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: May increase the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LORazepam: Valproate Products may increase the serum concentration of LORazepam.  Management: Reduce lorazepam dose 50% during coadministration with valproate products. Monitor for increased lorazepam effects, particularly CNS depression. Patients taking lorazepam extended-release capsules should be switched to lorazepam tablets.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May diminish the therapeutic effect of Antiseizure Agents. Mefloquine may decrease the serum concentration of Antiseizure Agents. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If antiseizure drugs are being used for another indication, monitor antiseizure drug concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylfolate: May decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antiseizure Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May diminish the therapeutic effect of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minoxidil (Systemic): Valproate Products may increase the serum concentration of Minoxidil (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Valproate Products may decrease the serum concentration of OLANZapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: Valproate Products may decrease the serum concentration of OXcarbazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salts (Calcium, Magnesium, Potassium, and Sodium): Valproate Products may increase the serum concentration of Oxybate Salts (Calcium, Magnesium, Potassium, and Sodium).  Management: Decrease the dose of oxybate salts by at least 20% when initiating therapy with valproate products. When initiating oxybate salts in patients taking valproate products, use a lower starting dose of oxybate salts.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Valproate Products may increase the serum concentration of Paliperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: Valproate Products may enhance the CNS depressant effect of Perampanel. Perampanel may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pivalate-Conjugated Medications: May enhance the adverse/toxic effect of Valproate Products. Specifically, the risk for decreased carnitine concentrations is increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pivmecillinam: Valproate Products may enhance the adverse/toxic effect of Pivmecillinam. Specifically, the risk for carnitine deficiency may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: Valproate Products may increase the serum concentration of Primidone. More specifically, the serum concentration of phenobarbital, primidone's primary active metabolite, may be increased. Primidone may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: Valproate Products may enhance the therapeutic effect of Propofol.  Management: Decrease the propofol dose and monitor for sedation and cardiorespiratory depression during coadministration with valproate products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Valproate Products may enhance the adverse/toxic effect of RisperiDONE. Generalized edema has developed. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Valproate Products may diminish the therapeutic effect of Rivaroxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: Valproate Products may increase the serum concentration of Rufinamide.  Management: Initiate rufinamide at a dose less than 10 mg/kg/day (children) or 400 mg/day (adults) in patients receiving valproic acid. In patients receiving rufinamide, initiate valproic acid at a low dose and titrate based on clinical response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May increase the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sapropterin: Valproate Products may decrease the serum concentration of Sapropterin. Specifically, valproate products may decrease tissue concentrations of tetrahydrobiopterin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Valproate Products may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Oxybate: Valproate Products may increase the serum concentration of Sodium Oxybate.  Management: Decrease the dose of sodium oxybate immediate release oral solution by at least 20% when initiating therapy with valproate products. No dose adjustment recommended when sodium oxybate extended release suspension is combined with valproate products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: Histone Deacetylase Inhibitors may enhance the adverse/toxic effect of Taurursodiol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temozolomide: Valproate Products may enhance the adverse/toxic effect of Temozolomide. Valproate Products may increase the serum concentration of Temozolomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: May enhance the adverse/toxic effect of Valproate Products. Specifically, the risk of hypothermia and hyperammonemia, with or without encephalopathy, may be increased. Valproate Products may decrease the serum concentration of Topiramate. Topiramate may decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: Valproate Products may increase the serum concentration of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urea Cycle Disorder Agents: Valproate Products may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Valproate Products may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Valproate Products may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorinostat: Valproate Products may enhance the thrombocytopenic effect of Vorinostat. This may increase the risk of gastrointestinal bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: Valproate Products may increase the serum concentration of Zidovudine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F233015"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Food may delay but does not affect the extent of absorption. Management: May administer with food if GI upset occurs.</p></div>
<div class="block rep_considerations drugH1Div" id="F52886548"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">
<b>Valproate is contraindicated for prophylaxis of migraine headaches in patients of childbearing potential who are not using effective contraception.</b></p>
<p style="text-indent:0em;margin-top:2em;">
<b>Valproate should not be used to treat patients with epilepsy or bipolar disorder who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable.</b></p>
<p style="text-indent:0em;margin-top:2em;">Evaluate pregnancy status in patients who could become pregnant (Larsen 2015; Toledo 2021). Patients with epilepsy prescribed valproate should be switched to other agents prior to menarche (Toledo 2021). Counsel patients at the onset of puberty and regularly during therapy regarding risks and benefits of valproate if pregnancy should occur during treatment. <b>Valproate should not be administered to a patient of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable</b>. If valproate therapy is required in patients who could become pregnant, highly effective individualized contraception should be used. When use of valproate is required in patients with epilepsy who could become pregnant, the minimum effective dose should be used, and slow-release formulations should be prescribed (to avoid high peak concentrations) (Toledo 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Algorithms are available for the management of patients who are planning a pregnancy or could have an unexpected pregnancy while taking valproic acid for bipolar disorder. Nonpregnant patients who are stable on monotherapy and are planning a pregnancy should undergo a slow taper (&gt;4 weeks); alternative treatment and a faster taper should be introduced in unstable patients during this time. Additional details are available for patients planning a pregnancy who are on multiple medications (Anmella 2019).</p>
<p style="text-indent:0em;margin-top:2em;">When pregnancy is being planned in patients with epilepsy, consider tapering off of therapy prior to conception if appropriate (Anmella 2019; Harden 2009a); abrupt discontinuation of therapy may cause status epilepticus and lead to maternal and fetal hypoxia. Pregnancies should be planned 1 year prior to conception, ≥ 1 month after the last valproate dose during a seizure-free period. Contraception should continue for 3 months after discontinuing valproate and transitioning to a new antiepileptic medication (Toledo 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Counsel patients planning to become pregnant regarding benefits and risk of valproate use during pregnancy. Folic acid decreases the risk of neural tube defects in the general population; supplementation with folic acid should be used prior to conception and during pregnancy in all patients, including those taking valproate.</p>
<p style="text-indent:0em;margin-top:2em;">Infertility, irregular menses, secondary amenorrhea, polycystic ovary syndrome, aspermia, azoospermia, decreased sperm count and motility, and abnormal sperm morphology have been reported following valproate use.</p></div>
<div class="block pri drugH1Div" id="F233002"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Valproate crosses the placenta (Harden 2009b).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Valproate can cause major congenital malformations, particularly neural tube defects (eg, spina bifida). In addition, valproate can cause decreased IQ scores and neurodevelopmental disorders following in utero exposure.</b> Neural tube defects, craniofacial defects (eg, oral clefts, craniosynostosis), cardiovascular malformations, hypospadias, and limb malformations (eg, clubfoot, polydactyly) have been reported. Information from the North American Antiepileptic Drug Pregnancy Registry notes the rate of major malformations to be 9% to 11% following an average exposure to valproate monotherapy 1,000 mg/day; this is an increase in congenital malformations when compared with monotherapy with other antiseizure drugs (AED). Based on data from the CDC National Birth Defects Prevention Network, the risk of spinal bifida is approximately 1% to 2% following valproate exposure (general population risk estimated to be 0.06% to 0.07%).</p>
<p style="text-indent:0em;margin-top:2em;">Nonteratogenic adverse effects have also been reported. Decreased IQ scores have been noted in children exposed to valproate in utero when compared to children exposed to other antiseizure medications or no antiseizure medications; the risk of autism spectrum disorders and attention deficit/hyperactivity disorder may also be increased. Hearing loss or impairment may occur following in utero exposure. Fatal hepatic failure and hypoglycemia in infants have been noted in case reports following in utero exposure to valproate.</p>
<p style="text-indent:0em;margin-top:2em;">The pharmacokinetic properties of valproate in pregnancy are highly variable. If use is needed, monitoring of total and unbound serum concentrations should be done prior to and during pregnancy (Johannessen 2018). Clotting factor abnormalities (hypofibrinogenemia, thrombocytopenia, or decrease in other coagulation factors) may develop in the mother following valproate use during pregnancy; close monitoring of coagulation factors is recommended.</p>
<p style="text-indent:0em;margin-top:2em;">Due to the risks of adverse fetal events, <b>valproate is contraindicated for prophylaxis of migraine headaches in pregnant patients. Valproate should not be used to treat pregnant patients with epilepsy or bipolar disorder unless other medications have failed to provide adequate symptom control or are otherwise unacceptable.</b> Current guidelines recommend complete avoidance of valproate for the treatment of epilepsy in pregnant patients whenever possible (Harden 2009a).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to valproate is ongoing. A pregnancy registry is available for patients who have been exposed to valproic acid. Patients may enroll themselves in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling (888) 233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>
<div class="block mopp drugH1Div" id="F53569402"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Liver enzymes (prior to therapy and at frequent intervals, especially during the first 6 months), bilirubin, serum ammonia (with symptoms of lethargy, mental status change), CBC with platelets (prior to initiation and periodically during therapy), vitamin D levels, bodyweight, serum concentrations, PT/PTT (especially prior to surgery); signs and symptoms of suicidality (eg, anxiety, depression, behavior changes), motor and cognitive function, persistent vomiting</p></div>
<div class="block rerp drugH1Div" id="F53568992"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">In general, trough concentrations should be used to assess adequacy of therapy; peak concentrations may also be drawn if clinically necessary (eg, concentration-related toxicity). When extended-release tablets are administered at bedtime, levels drawn ≥18 hours postdose have been suggested to provide an acceptable estimate of trough concentrations when levels timed closer to the next dose are inconvenient (eg, during outpatient monitoring) (Kernitsky 2005; Reed 2006).</p>
<p style="text-indent:0em;margin-top:2em;">Patient-specific factors must be taken into consideration when interpreting drug concentrations, including indication, age (particularly pediatric patients), clinical response, pregnancy status, adherence, comorbidities, adverse effects, and concomitant medications (Patsalos 2018; Reed 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Valproic acid, total: </i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Seizure disorder</b>: Infants, Children, Adolescents, and Adults:</p>
<p style="text-indent:-2em;margin-left:6em;">A target range of 50 to 100 mcg/mL (SI: 346 to 693 micromole/L) is generally recognized (Patsalos 2018), although in pediatric patients (particularly neonates and young infants), the relationship between total plasma concentration and therapeutic response is not well documented (Panomvana Na Ayudhya 2006; Ueshima 2009); individualized therapeutic concentration ranges for seizure control may be necessary; some patients may improve at total serum levels &gt;100 mcg/mL (SI: 700 micromole/L), and toxicity may occur at levels of 100 to 150 mcg/mL (SI: 693 to 1,038 micromole/L).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mania:</b> Adult: Therapeutic trough: 50 to 125 mcg/mL (SI: 350 to 875 micromole/L).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Valproic acid, free: </i>In pediatric patients, reported ranges are variable and have not been defined; determination of a therapeutic free range should be individualized (Panomvana Na Ayudhya 2006; Ueshima 2009). In pediatric patients, higher serum concentrations were observed to have a higher percentage of unbound valproic acid (nonlinear relationship) (Panomvana Na Ayudhya 2006). Monitoring free valproic acid serum concentrations should be considered in some clinical situations which may include the following: Pediatric patients; patients with renal or hepatic dysfunction, low serum albumin, elevated total serum valproic acid concentration, significant drug interactions that may displace valproic acid drug from protein sites, less than desired therapeutic response, or pregnancy (Patsalos 2018; Wallenburg 2017; manufacturer's labeling). In adult patients, a therapeutic free serum range of 5 to 15 mcg/mL has been suggested (Smetana 2016).</p></div>
<div class="block pha drugH1Div" id="F232978"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Causes increased availability of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, to brain neurons or may enhance the action of GABA or mimic its action at postsynaptic receptor sites. Also blocks voltage-dependent sodium channels, which results in suppression of high-frequency repetitive neuronal firing (Bourin 2009). Divalproex sodium is a compound of sodium valproate and valproic acid; divalproex dissociates to valproate in the GI tract.</p></div>
<div class="block phk drugH1Div" id="F232997"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Distributes into CSF at concentrations similar to unbound concentration in plasma (ie, ~10% of total plasma concentration)</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>: Total valproate: 11 L/1.73 m<sup>2</sup>; Free valproate 92 L/1.73 m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding (concentration dependent): 80% to 90%; free fraction: ~10% at 40 mcg/mL and ~18.5% at 130 mcg/mL; protein binding decreased in neonates, the elderly and patients with hepatic or renal impairment</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via glucuronide conjugation (30% to 50% of administered dose) and 40% via mitochondrial beta-oxidation; other oxidative metabolic pathways occur to a lesser extent.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Extended release: ~90% relative to IV dose and ~89% relative to delayed release formulation. In pediatric patients 10 to 17 years of age, once-daily administration of the ER formulation produced valproate plasma concentration-time profiles similar to adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination (increased in neonates, elderly, and patients with liver impairment):</p>
<p style="text-indent:-2em;margin-left:4em;">Newborns (exposed to VPA in utero): 30 to 60 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates first week of life: 40 to 45 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates &lt;10 days: 10 to 67 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;2 months: 7 to 13 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 2 to 14 years: 9 hours (range: 3.5 to 20 hours) (Cloyd 1993)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 9 to 19 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Divalproex sodium:</p>
<p style="text-indent:-2em;margin-left:8em;">Delayed release: tablet and sprinkle capsules: ~4 hours</p>
<p style="text-indent:-2em;margin-left:8em;">Extended release: 4 to 17 hours</p>
<p style="text-indent:-2em;margin-left:8em;">Immediate release enteric-coated tablet [Canadian product]: 4 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Valproic acid delayed release capsule: 2 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal (off-label route): 1 to 3 hours (Graves 1987)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (30% to 50% as glucuronide conjugate, &lt;3% as unchanged drug); faster clearance in children who receive other antiseizure drugs and those who are younger; age and polytherapy explain 80% of interpatient variability in total clearance; children &gt;10 years of age have pharmacokinetic parameters similar to adults</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Note:</b> ER formulation has 10% to 20% less fluctuation in serum concentration than delayed release formulation. ER formulation is not bioequivalent to delayed release formulation.</p></div>
<div class="block phksp drugH1Div" id="F51204419"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: A 27% reduction in clearance of unbound valproate is seen in patients with CrCl &lt;10 mL/minute. Hemodialysis reduces valproate concentrations by 20%. Therefore, no dosage adjustment appears to be necessary in patients with renal failure. Protein binding is reduced. Monitoring of free valproate concentrations may be of clinical value; total valproate concentrations may be misleading.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Clearance is decreased with liver impairment. Hepatic disease is also associated with decreased albumin concentrations and 2- to 2.6-fold increase in the unbound fraction. Free concentrations of valproate may be elevated while total concentrations appear normal.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F233005"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Depakine | Depakine chrono | Dicorate | Valopin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Depakene | Diproval | Divalprex | Exibral | Flaxvan | Improval | Logical | Proval | Valcas | Valcote | Valnar</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Convulex | Depakine chrono | Leptilanil | Natriumvalproat | Natriumvalproat G.L. | Natriumvalproat salutas | Natriumvalproat sandoz</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo sodium valproate | Epilim | Sodium valproate juno | Sodium Valproate Sandoz | Sodium valproate wockhardt | Valprease | Valpro | Valproate Winthrop</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Convules | Encorate | Encorate chrono | Epilim | Epilim chrono | Epival | Proval | Sodival | Sodival cr | Soval | Valex | Valoate</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Convulex | Convulex retard | Depakine | Depakine chrono | Valproaat retard | Valproate eg | Valproate Sandoz</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Depakine | Depakine chrono | Valporate de sodium zentiva | Valproate de sodium zentiva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Convulex | Convulex Chrono | Convulsofin | Depakin | Depakin chrono | Orfiril</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acido valproico | Depacon | Depakene | Depakote | Divalcon er | Divalproato de sodio | Epilenil | Lavie | Torval | Valpakine | Valparin | Valpi | Valprene | Valproato de sodio | Valproato sodico | Vodsso | Zyvalprex</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Convulex | Depakine | Depakine chrono | Orfiril | Valproat Chrono | Valproate chrono zentiva</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Valproate de sodium zentiva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Atemperator | Depakene | Di VP | Divalprex | Leptilan | Neuractin | Valcote</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Depakine | Depakine chrono | Dian tai | Epilim | Mag.valproate | Magnesium valproate | Sodium valproate</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acido valproico | Atemperator | Depakene | Dicorate | Dicorate ER | Epigel | Ferbin | Neuractin | Provalnova | Valcid | Valcote | Valprolife | Valprosid | Valsup</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Absenor | Convulex | Depakine chrono | Everiden | Orfiril | Valproat Ratiopharm</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Convulex | Convulsofin | Depakine chrono | Emolone | Ergenyl | Espa Valept | Leptilan | Orfiril | Orfiril chrono | Valberg | Valdia | Valhel | Valpro | Valpro AL | Valpro beta | Valpro beta chrono | Valpro chrono | Valproat | Valproat 1A Pharma | Valproat Aristo | Valproat awd | Valproat biomo | Valproat Chrono | Valproat Chrono CT | Valproat chrono glenmark | Valproat Heumann | Valproat hexal | Valproat Hexal Chrono | Valproat Neuraxpharm Chrono | Valproat sandoz | Valproat Stada | Valproat-ct | Valproat-RPh | Valprodura | Valproinsaeure | Valproinsaeure ratiopharm chrono | Valproinsaeure-ratiopharm chrono | Valprolept | Valsil | Valsun</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Delepsine</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Acido valproico | Atemperator | Atemperator LP | Convulex | Divalprex | Epival | Espertal | Valpakine | Valpro | Valproato Exels | Valprolam</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acido valproico | Atemperator | Convuloxial | Criam | Leptilan | Valcote | Valpakine | Valproato sodico</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Absenor | Apilepsin | Convulex | Depakine | Depakine chrono | Orfiril | Valproate Sandoz | Valproate sodium Sandoz</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Convulex | Daviken | Dekadel | Depakine | Depakine chrono | Depalept | Depavalpolem | DivaKote | Mentavers | Seizolow | Valpoeast | Valpokine | Valponex | Valproex | Valprotec | Vedge | Xoplict</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Acido Valproico Aurovitas | Depakine | Depakine crono | Milzone</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Petilin | Pravia cr | Sodium valproate</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Absenor | Deprakine | Leptilan | Orfiril | Orfiril desitin | Valproat sandoz</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Depakine | Depakine chrono | Depakote | Divalcote | Valproate de sodium Alter | Valproate de sodium Arrow | Valproate de sodium biogaran | Valproate de sodium EG | Valproate de sodium irex | Valproate de sodium qualimed | Valproate de sodium ratiopharm | Valproate de sodium RPG | Valproate de sodium sandoz | Valproate de sodium winthrop</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Belvo | Convulex | Depakote | Dyzantil | Epilim | Epival | Orlept | Sodium valproate | Syonell</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Depakine | Depakine chrono</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Epilim | Sodium valproate | Valpro</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Apilepsin | Depakine chrono</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Convulex | Depakine | Depakine chrono | Everiden | Orfiril</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Asam valproat ikapharmindo | Depakene | Depakote | Depakote er | Divalpi | Divalproex | Garkene | Ikalep | Lepsio | Leptilan | Phalsy | Valkene | Valpi | Valproic acid | Vellepsy</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Depakote | Epilim | Epilim chrono</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Depalept | Depalept chrono | Valporal</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alporate | Alproate | Anteleptin | Ap chrono | Binaprex | Brival | Bypol | Cinaval Chrono | Cizfree cr | Convulex | D val er | Dayo | Depakote | Desval | Devot | Diavox | Dicor | Dicorate | Diepirate | Dilex | Dilpra | Diporex | Diprate od | Dipro 500 | Dipro od | Diproex | Diresta | Diresta od | Disorate | Disoval | Divaa | Divacid er | Divalcad er | Divalep | Divalex od | Divalgress | Divalid er | Divalox er | Divalprid | Divalpro | Divarus er | Divotek | Divox | Divuna | Diwok | Dixval | Doval cr | Elival | Encorate | Encorate chrono | Epilex | Epilex Chrono | Epival | Epsoval | Espoval | Genval cr | Genval od | Kronostar | Leps cr | Macorate | Magval | Manoval | Napilex | Napilex CR | Neoprate | Novalept chrono | Proval | Rex XR | Senval chrono | Seprodex | Sodaval | Solprate | Soval chrono | Soval dvx | Sovam cr | Tikoprex | Torvate | Torvate Chrono | Trend | Trival cr | Val | Valance | Valate | Valate Chrono | Valcip | Valcontin | Valep-chrono | Valeptol cr | Valex | Valkem | Valkem od | Valna | Valnex cr | Valox cr | Valp | Valp-na | Valparin | Valparin chrono | Valpex | Valpo | Valpo cr | Valporate chrono | Valporil | Valprid | Valprid cr | Valprol | Valprol cr | Valrate | Valrate cr | Valtec | Valtril | Valvo cr | Vap | Vap dxr | Vat cr | Velze | Vikorate | Vikorate chrono</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">AC Val/S Valp EG | Acido Valproico Sandoz | Depakin | Depakin chrono | Depakin Chrono | Depamag | Sodio Valproato Aurobindo</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Convulex | Depakine | Depakine chrono | Epival</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Baldeken-r | Cebotval | Cebotval amel | Cebotval bmj | Depakene | Depakene-r | Epirenat | Esdouble | Hyserenin | Patolos | Sanoten | Selenica r | Selenica r nikken | Valerin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Braiporin | Encorate | Encorate chrono | Epilim | Epilim chrono</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Depacon | Depakine | Depakine chrono | Depakote | Depakote er | Depakote sprinkle | Depamak | Epilam | Epival | Oltril | Orfil | Palporan | Promac | Promag | Revbal | Valeptol | Valoin | Valoin-a | Valpics | Valpin | Valpon | Valpro | Vipro</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Depakine | Depakine chrono | Depakote | Epival</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Convulex | Depakine | Valpro tad chrono | Valproate de sodium biogaran</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Acediprol | Apilepsin | Convulex | Convulsofin | Depakine | Depakine chrono | Everiden | Orfiril | Prodepa | Valproate sodium Sandoz</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Convulex | Depakine | Valproate eg | Valproinsaure chrono</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Acediprol | Apilepsin | Convulex | Depakin | Depakine | Depakine chrono | Ergenyl | Ergenyl chrono | Everiden | Orfiril | Valproate Sandoz</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Depakine | Depakine chrono | Encorate</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acido Valproico | Apoproa | Atemperator | Atemperator LP | Criam | Depakene | Diwali | Edorame | Edorame lp | Edorame sem | Epival | Epival er | Epival sprinkle | Leptilan | Otaorplan m | Pimiken | Sincretone | Trankitec | Valoudes | Valproato de magnesio | Valproato de magnesio landsteiner | Valprosid | Vamegist | Vematina | Vupelsat</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Encorate | Epilim | Epilim chrono | Leptilan | Orfiril | Unival</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Encorate chrono | Epilim | Excel charis sodium valproate | Pravia cr | Racex | Valpro xr</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Depakine | Depakine chrono | Depakine enteric | Depakine zuur | Natrii valproas | Natriumvalproaat | Natriumvalproaat Alpharma | Natriumvalproaat CF | Natriumvalproaat Enteric Winthrop | Natriumvalproaat PCH | Natriumvalproaat ratiopharm | Natriumvalproaat Sandoz | Natriumvalproaat teva | Orfiril | Propymal</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Deprakine | Divalproex sodium | Orfiril | Valproat life</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Epilim</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Acido valproico | Depakene | Di viterma | Di-Valprax | Dicorate | Divalprax | Divalprid | Epival | Orfiril | Valcote | Valpakine | Valpakine crono | Valprax | Valproato sodico | Valpromed</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Akudiva | Convulzor | Depacon | Depakene | Depakote | Depamax | Dicorate ER | Divalgen | Divalproex | Encorate | Encorate chrono | Epival | Lepsio | Valparin | Valpros | Valpros pedia | Zystal</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Dapakan | Dipodium | Diprate sr | Divalpro | Epilim | Epival | Evalpro | Orifral | Perval | Revalp | Sigval | Twoprox | Uni val | Valpro | Valpromed | Valrox | W val | Wapival</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Absenor | Apilepsin | Convival Chrono | Convulex | Depakine | Depakine chrono | Dipromal | Everiden | Leptilan | Orfiril | Valprolek</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Depacon | Depakene | Depakote | Depakote er | Divalproex sodium | Stavzor | Valproate | Valproic acid</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Acido Valproico Generis | Acido Valproico Ratiopharm | Acido valproico sandoz | Depakine | Depakine chrono | Diplexil | Diplexil-R | Valproato</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Convulsedan | Cronoval | Depakene | Diplonat | Divalp | Divalprex | Divalproato de sodio bioethic pharma | Flaxvan | Logical | Neuractin | Neuractin sr | Valcote | Valcote er | Valepsia lp | Valgen | Valpakine | Valpron</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Convulex | Convulsofin | Depakine | Orfiril | Valparin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Acediprol | Apilepsin | Convulex | Convulsofin | Convulsofin retard | Depakin | Depakin chrono | Depakine | Depakine chrono | Encorate | Encorate chrono | Valopixim | Valparin XR | Valproic acid | Valproic acid sandoz</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Depakine | Depakine chronodose | Epival | Sodium valproate | Valopin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Absenor | Depakine retard | Ergenyl | Ergenyl retard | Orfiril</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Convulex | Epilim | Epilim chrono | Leptilan | Sodium valproate wockhardt | Valparin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Apilepsin | Convulex | Depakine chrono</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Absenor | Convulex | Depakine | Depakine chrono | Everiden | Orfiril | Valproat Ratiopharm</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Depakine | Depakine chrono | Desorate | Encorate | Encorate chrono | Sodium valproate | Valparin | Valrem</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Convulex | Depakine | Depakine chrono | Ergenyl | Valoxine | Valproate de sodium mylan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Convulex | Depakin | Depakin chrono bt | Depakine | Depalex xr | Epilepkin | Navarin | Valeptik XR | Valposim</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Apo-Divalproex | Cebotval | Convulex | Depakene | Depakine | Depakine chrono | Depavent | Dinsia | Dipachro | Divaprodium | Laxymig | Leptilan | Vakin chrono | Valnon | Valpro | Valprotine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Convulex | Convulex retard | Convulsofin | Depakine | Depakine chrono | Depakine enteric | Dipromal | Encorat | Encorat Chrono | Encorate chrono | Everiden | Orfiril | Valproat orion | Valproate teva</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Divaa od | Epilim | Epilim chrono | Epival | Petilin | Valate | Valcontin | Valparin chrono</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dan | Depakene | Di dpa | Di-Dpa | Di-dpa 250 | DPA | Dpa | Leptilan | Logical | Valcote | Valcote er | Valnar</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acido valproico | Avalpric | Depakine | Flaxvan | Valcote | Valpron</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Convulex | Epilim | Eprolep | Navalpro | Valeptic cr | Vanapro</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Epilim cr | Epipro 300 cr | Epipro 500 cr | Valparin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Epiproate cr | Torvate</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-HazardousDrugs.2017">
<a name="HazardousDrugs.2017"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10695824">
<a name="10695824"></a>Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. <i>J Pediatr Hematol Oncol</i>. 2000;22(1):62-65. doi:10.1097/00043426-200001000-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/10695824/pubmed" id="10695824" target="_blank">10695824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17616473">
<a name="17616473"></a>Agarwal P, Kumar N, Chandra R, Gupta G, Antony AR, Garg N. Randomized study of intravenous valproate and phenytoin in status epilepticus. <i>Seizure</i>. 2007;16(6):527-532.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/17616473/pubmed" id="17616473" target="_blank">17616473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21147182">
<a name="21147182"></a>Aires CC, van Cruchten A, Ijlst L, et al. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. <i>J Hepatol</i>. 2011;55(2):426-434. doi:10.1016/j.jhep.2010.11.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/21147182/pubmed" id="21147182" target="_blank">21147182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8783377">
<a name="8783377"></a>Akaho R. The effects of antiepileptic drugs on cognition in normal volunteers. <i>Psychiatry Clin Neurosci</i>. 1996;50(2):61-69. doi:10.1111/j.1440-1819.1996.tb01665.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/8783377/pubmed" id="8783377" target="_blank">8783377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20354855">
<a name="20354855"></a>Albayrak F, Cerrah S, Albayrak A, Dursun H, Yildirim R, Uyanik A. DRESS syndrome with fatal results induced by sodium valproate in a patient with brucellosis and a positive cytoplasmic antineutrophilic cytoplasmic antibody test result. <i>Rheumatol Int</i>. 2012;32(7):2181-2184. doi:10.1007/s00296-010-1463-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/20354855/pubmed" id="20354855" target="_blank">20354855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-373647">
<a name="373647"></a>Alexander FW. Sodium valproate and pregnancy. <i>Arch Dis Child</i>. 1979;54(3):240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/373647/pubmed" id="373647" target="_blank">373647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26336183">
<a name="26336183"></a>Al-sharefi A, Bilous R. Reversible weakness and encephalopathy while on long-term valproate treatment due to carnitine deficiency. <i>BMJ Case Rep</i>. 2015;2015:bcr2015210727. doi:10.1136/bcr-2015-210727<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/26336183/pubmed" id="26336183" target="_blank">26336183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29761006">
<a name="29761006"></a>Amiri-Nikpour MR, Nazarbaghi S, Eftekhari P, et al. Sodium valproate compared to phenytoin in treatment of status epilepticus. <i>Brain Behav</i>. 2018;8(5):e00951. doi:10.1002/brb3.951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/29761006/pubmed" id="29761006" target="_blank">29761006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30003428">
<a name="30003428"></a>Anderson GD, Hakimian S. Pharmacokinetic factors to consider in the selection of antiseizure drugs for older patients with epilepsy. <i>Drugs Aging</i>. 2018;35(8):687-698. doi:10.1007/s40266-018-0562-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/30003428/pubmed" id="30003428" target="_blank">30003428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26033949">
<a name="26033949"></a>Anderson M, Egunsola O, Cherrill J, Millward C, Fakis A, Choonara I. A prospective study of adverse drug reactions to antiepileptic drugs in children. <i>BMJ Open</i>. 2015;5(6):e008298. doi:10.1136/bmjopen-2015-008298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/26033949/pubmed" id="26033949" target="_blank">26033949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31590972">
<a name="31590972"></a>Anmella G, Pacchiarotti I, Cubała WJ, et al. Expert advice on the management of valproate in women with bipolar disorder at childbearing age. <i>Eur Neuropsychopharmacol</i>. 2019;29(11):1199-1212. doi: 10.1016/j.euroneuro.2019.09.007.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/31590972/pubmed" id="31590972" target="_blank">31590972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18705027">
<a name="18705027"></a>Apostol G, Cady RK, Laforet GA, et al. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. <i>Headache</i>. 2008, 48(7):1012-1025.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/18705027/pubmed" id="18705027" target="_blank">18705027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19040679">
<a name="19040679"></a>Apostol G, Lewis DW, Laforet GA, et al. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study. <i>Headache</i>. 2009a;49(1):45-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19040679/pubmed" id="19040679" target="_blank">19040679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19040678">
<a name="19040678"></a>Apostol G, Pakalnis A, Laforet GA, et al. Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches: results of an open-label extension trial in adolescents. <i>Headache</i>. 2009b;49(1):36-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19040678/pubmed" id="19040678" target="_blank">19040678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818889">
<a name="20818889"></a>Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. <i>N Engl J Med</i>. 2010;363(6):542-551. doi:10.1056/NEJMoa0909801<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/20818889/pubmed" id="20818889" target="_blank">20818889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6814902">
<a name="6814902"></a>Asconapé JJ, Penry JK. Use of antiepileptic drugs in the presence of liver and kidney diseases: a review. <i>Epilepsia</i>. 1982;(23)(suppl 1):S65-S79. doi:10.1111/j.1528-1157.1982.tb06092.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/6814902/pubmed" id="6814902" target="_blank">6814902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24365310">
<a name="24365310"></a>Asconapé JJ. Use of antiepileptic drugs in hepatic and renal disease. <i>Handb Clin Neurol</i>. 2014;119:417-432. doi: 10.1016/B978-0-7020-4086-3.00027-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/24365310/pubmed" id="24365310" target="_blank">24365310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16120482">
<a name="16120482"></a>Ashrafi MR, Shabanian R, Zamani GR, Mahfelati F. Sodium Valproate versus Propranolol in paediatric migraine prophylaxis. <i>Eur J Paediatr Neurol</i>. 2005;9(5):333-338.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/16120482/pubmed" id="16120482" target="_blank">16120482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30293233">
<a name="30293233"></a>Baillon SF, Narayana U, Luxenberg JS, Clifton AV. Valproate preparations for agitation in dementia. <i>Cochrane Database Syst Rev</i>. 2018;10(10):CD003945. doi:10.1002/14651858.CD003945.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/30293233/pubmed" id="30293233" target="_blank">30293233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31721077">
<a name="31721077"></a>Baizabal-Carvallo JF, Alonso-Juarez M. Valproate-induced rest tremor and parkinsonism. <i>Acta Neurol BelgB</i>. 2019 Nov 13. doi:10.1007/s13760-019-01239-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/31721077/pubmed" id="31721077" target="_blank">31721077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31799506">
<a name="31799506"></a>Bassett JT, Rodriguez B, Mulligan L, Fontana RJ. Acute liver failure in a military recruit treated with valproic acid and harboring a previously unrecognized POLG-1 mutation. <i>Epilepsy Behav Rep</i>. 2019;12:100342. doi:10.1016/j.ebr.2019.100342<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/31799506/pubmed" id="31799506" target="_blank">31799506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17913733">
<a name="17913733"></a>Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A. Hyponatremia associated with sodium valproate in a 22-year-old male. <i>Nephrol Dial Transplant</i>. 2008;23(1):410. doi:10.1093/ndt/gfm682<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/17913733/pubmed" id="17913733" target="_blank">17913733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19453718">
<a name="19453718"></a>Bell GS, Gaitatzis A, Bell CL, Johnson AL, Sander JW. Suicide in people with epilepsy: how great is the risk? <i>Epilepsia</i>. 2009;50(8):1933-1942. doi:10.1111/j.1528-1167.2009.02106.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19453718/pubmed" id="19453718" target="_blank">19453718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28190254">
<a name="28190254"></a>Bellivier F, Belzeaux R, Scott J, Courtet P, Golmard JL, Azorin JM. Anticonvulsants and suicide attempts in bipolar I disorders. <i>Acta Psychiatr Scand</i>. 2017;135(5):470-478. doi:10.1111/acps.12709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/28190254/pubmed" id="28190254" target="_blank">28190254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17696575">
<a name="17696575"></a>Bialer M. Extended-release formulations for the treatment of epilepsy. <i>CNS Drugs</i>. 2007;21(9):765-774. doi:10.2165/00023210-200721090-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/17696575/pubmed" id="17696575" target="_blank">17696575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18341684">
<a name="18341684"></a>Björnsson E. Hepatotoxicity associated with antiepileptic drugs. <i>Acta Neurol Scand</i>. 2008;118(5):281-290. doi:10.1111/j.1600-0404.2008.01009.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/18341684/pubmed" id="18341684" target="_blank">18341684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24001084">
<a name="24001084"></a>Bleck T, Cock H, Chamberlain J, et al. The established status epilepticus trial 2013. <i>Epilepsia</i>. 2013;54 Suppl 6:89-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/24001084/pubmed" id="24001084" target="_blank">24001084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21841930">
<a name="21841930"></a>Bota RG, Ligasan AP, Najdowski TG, Novac A. Acute hypersensitivity syndrome caused by valproic Acid: a review of the literature and a case report. <i>Perm J</i>. 2011;15(2):80-84. doi:10.7812/tpp/10-140<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/21841930/pubmed" id="21841930" target="_blank">21841930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19702557">
<a name="19702557"></a>Bourin M, Chenu F, Hascoët M. The role of sodium channels in the mechanism of action of antidepressants and mood stabilizers. <i>Curr Drug Targets</i>. 2009;10(11):1052-1060.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19702557/pubmed" id="19702557" target="_blank">19702557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20101186">
<a name="20101186"></a>Bowden CL, Mosolov S, Hranov L, et al. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. <i>Int Clin Psychopharmacol</i>. 2010;25(2):60-67. doi: 10.1097/YIC.0b013e328333ac1b.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/20101186/pubmed" id="20101186" target="_blank">20101186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17107240">
<a name="17107240"></a>Bowden CL, Swann AC, Calabrese JR, et al. Depakote ER Mania Study Group. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. <i>J Clin Psychiatry</i>. 2006;67(10):1501-1510.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/17107240/pubmed" id="17107240" target="_blank">17107240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22528274">
<a name="22528274"></a>Brophy GM, Bell R, Claassen J, et al. Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/22528274/pubmed" id="22528274" target="_blank">22528274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29260458">
<a name="29260458"></a>Buoli M, Serati M, Botturi A, Altamura AC. The risk of thrombocytopenia during valproic acid therapy: A critical summary of available clinical data. <i>Drugs R D</i>. 2018;18(1):1-5. doi:10.1007/s40268-017-0224-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/29260458/pubmed" id="29260458" target="_blank">29260458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10971664">
<a name="10971664"></a>Caruso JM, Brown WD, Exil G, Gascon GG. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. <i>Headache</i>. 2000;40(8):672-676.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/10971664/pubmed" id="10971664" target="_blank">10971664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice parameters Committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32203691">
<a name="32203691"></a>Chamberlain JM, Kapur J, Shinnar S, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. <i>Lancet</i>. 2020;395(10231):1217-1224. doi:10.1016/S0140-6736(20)30611-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/32203691/pubmed" id="32203691" target="_blank">32203691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18262440">
<a name="18262440"></a>Chan K, Beran RG. Value of therapeutic drug level monitoring and unbound (free) levels. <i>Seizure</i>. 2008;17(6):572-575. doi:10.1016/j.seizure.2007.12.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/18262440/pubmed" id="18262440" target="_blank">18262440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10192594">
<a name="10192594"></a>Chen ST, Altshuler LL, Melnyk KA, Erhart SM, Miller E, Mintz J. Efficacy of lithium vs. valproate in the treatment of mania in the elderly: a retrospective study. <i>J Clin Psychiatry</i>. 1999;60(3):181-186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/10192594/pubmed" id="10192594" target="_blank">10192594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24132760">
<a name="24132760"></a>Cipriani A, Reid K, Young AH, Macritchie K, Geddes J. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. <i>Cochrane Database Syst Rev</i>. 2013;(10):CD003196. doi: 10.1002/14651858.CD003196.pub2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/24132760/pubmed" id="24132760" target="_blank">24132760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8422737">
<a name="8422737"></a>Cloyd JC, Fischer JH, Kriel RL, Kraus DM. Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. <i>Clin Pharmacol Ther</i>. 1993;53(1):22-29. doi:10.1038/clpt.1993.5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/8422737/pubmed" id="8422737" target="_blank">8422737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10475512">
<a name="10475512"></a>Conilleau V, Dompmartin A, Verneuil L, Michel M, Leroy D. Hypersensitivity syndrome due to 2 anticonvulsant drugs. <i>Contact Dermatitis</i>. 1999;41(3):141-144. doi:10.1111/j.1600-0536.1999.tb06105.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/10475512/pubmed" id="10475512" target="_blank">10475512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3128778">
<a name="3128778"></a>Connacher AA, Borsey DQ, Browning MC, Davidson DL, Jung RT. The effective evaluation of thyroid status in patients on phenytoin, carbamazepine or sodium valproate attending an epilepsy clinic. <i>Postgrad Med J</i>. 1987;63(744):841-845. doi:10.1136/pgmj.63.744.841<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/3128778/pubmed" id="3128778" target="_blank">3128778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26715390">
<a name="26715390"></a>Cook AM, Zafar MS, Mathias S, et al. Pharmacokinetics and clinical utility of valproic acid administered via continuous infusion. <i>CNS Drugs</i>. 2016;30(1):71-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/26715390/pubmed" id="26715390" target="_blank">26715390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3131043">
<a name="3131043"></a>Cotariu D, Zaidman JL. Valproic acid and the liver. <i>Clin Chem</i>. 1988;34(5):890-897.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/3131043/pubmed" id="3131043" target="_blank">3131043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29621091">
<a name="29621091"></a>Dautzenberg G, Nederlof M, Beekman A, Egberts T, Heerdink ER. Severe cognitive impairment associated with a high free but therapeutic total concentration of valproic acid due to hypoalbuminemia in an older patient with bipolar disorder. <i>J Clin Psychopharmacol</i>. 2018;38(3):265-268. doi:10.1097/JCP.0000000000000872<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/29621091/pubmed" id="29621091" target="_blank">29621091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15780695">
<a name="15780695"></a>Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. <i>J Affect Disord</i>. 2005;85(3):259-266. doi: 10.1016/j.jad.2004.09.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/15780695/pubmed" id="15780695" target="_blank">15780695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17960970">
<a name="17960970"></a>Davis LL, Li X, Bartolucci AA, Williford RB, Lowe JS. A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex. <i>J Clin Psychiatry</i>. 2007;68(10):1546-1551. doi:10.4088/jcp.v68n1012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/17960970/pubmed" id="17960970" target="_blank">17960970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21325101">
<a name="21325101"></a>de Maat MM, van Leeuwen HJ, Edelbroek PM. High unbound fraction of valproic acid in a hypoalbuminemic critically ill patient on renal replacement therapy. <i>Ann Pharmacother</i>. 2011;45(3):e18. doi:10.1345/aph.1P308<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/21325101/pubmed" id="21325101" target="_blank">21325101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Depacon.2020.05">
<a name="Depacon.2020.05"></a>Depacon (valproate sodium) [prescribing information]. North Chicago, IL: AbbVie Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Depakene.2020.05">
<a name="Depakene.2020.05"></a>Depakene (valproic acid) [prescribing information]. North Chicago, IL: AbbVie Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DepakeneSol.2020.07">
<a name="DepakeneSol.2020.07"></a>Depakene (valproic acid) oral solution [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Depakote.2020.05">
<a name="Depakote.2020.05"></a>Depakote (divalproex sodium) [prescribing information]. North Chicago, IL: AbbVie Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DepakoteDRTabs.2019.02">
<a name="DepakoteDRTabs.2019.02"></a>Depakote Delayed-Release Tablets [prescribing information]. North Chicago, IL: AbbVie Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DepakoteER.2020.05">
<a name="DepakoteER.2020.05"></a>Depakote ER (divalproex sodium) [prescribing information]. North Chicago, IL: AbbVie Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DepakoteSprinkle.2020.05">
<a name="DepakoteSprinkle.2020.05"></a>Depakote Sprinkle Capsules (divalproex sodium) [prescribing information]. North Chicago, IL: AbbVie Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28027180">
<a name="28027180"></a>Derin H, Derin S, Oltulu P, Özbek O, Çaksen H. Pediatric sialadenosis due to valproic acid. <i>J Craniofac Surg</i>. 2017;28(2):e127-e129. doi:10.1097/SCS.0000000000003303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/28027180/pubmed" id="28027180" target="_blank">28027180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17326798">
<a name="17326798"></a>de Vries L, Karasik A, Landau Z, Phillip M, Kiviti S, Goldberg-Stern H. Endocrine effects of valproate in adolescent girls with epilepsy. <i>Epilepsia</i>. 2007;48(3):470-477. doi:10.1111/j.1528-1167.2006.00953.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/17326798/pubmed" id="17326798" target="_blank">17326798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35313227">
<a name="35313227"></a>Dogruyol S, Gur STA, Akbas I, et al. Intravenous ibuprofen versus sodium valproate in acute migraine attacks in the emergency department: a randomized clinical trial. <i>Am J Emerg Med</i>. 2022;55:126-132. doi:10.1016/j.ajem.2022.02.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/35313227/pubmed" id="35313227" target="_blank">35313227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28574586">
<a name="28574586"></a>Doré M, San Juan AE, Frenette AJ, Williamson D. Clinical importance of monitoring unbound valproic acid concentration in patients with hypoalbuminemia. <i>Pharmacotherapy</i>. 2017;37(8):900-907. doi:10.1002/phar.1965<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/28574586/pubmed" id="28574586" target="_blank">28574586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19820401">
<a name="19820401"></a>Dreesman A, Hoorens A, Hachimi-Idrissi S. Multiple organ dysfunction syndrome: infection or hypersensitivity reaction?. <i>Eur J Emerg Med</i>. 2010;17(4):228-229. doi:10.1097/MEJ.0b013e3283311f04<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19820401/pubmed" id="19820401" target="_blank">19820401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3102998">
<a name="3102998"></a>Dreifuss FE, Santilli N, Langer DH, et al, “Valproic Acid Hepatic Fatalities: A Retrospective Review,” <i>Neurology</i>, 1987, 37(3):379-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/3102998/pubmed" id="3102998" target="_blank">3102998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31276904">
<a name="31276904"></a>Duman B, Can KC, Ağtaş-Ertan E, et al. Risk factors for valproic acid induced hyperammonemia and its association with cognitive functions. <i>Gen Hosp Psychiatry</i>. 2019;59:67-72. doi:10.1016/j.genhosppsych.2019.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/31276904/pubmed" id="31276904" target="_blank">31276904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15111693">
<a name="15111693"></a>Easterford K, Clough P, Kellett M, Fallon K, Duncan S. Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. <i>Neurology</i>. 2004;62(8):1435-1437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/15111693/pubmed" id="15111693" target="_blank">15111693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11903525">
<a name="11903525"></a>Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. <i>Headache</i>. 2001;41(10):976-980. doi:10.1046/j.1526-4610.2001.01191.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/11903525/pubmed" id="11903525" target="_blank">11903525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Epival.2020.05">
<a name="Epival.2020.05"></a>Epival (divalproex sodium) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9536846">
<a name="9536846"></a>Evans D, Levene M. Neonatal seizures. <i>Arch Dis Child Fetal Neonatal Ed.</i> 1998; 78(1):70-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/9536846/pubmed" id="9536846" target="_blank">9536846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCPS, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31756600">
<a name="31756600"></a>Fan D, Miao J, Fan X, Wang Q, Sun M. Effects of valproic acid on bone mineral density and bone metabolism: A meta-analysis. <i>Seizure</i>. 2019;73:56-63. doi:10.1016/j.seizure.2019.10.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/31756600/pubmed" id="31756600" target="_blank">31756600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29455082">
<a name="29455082"></a>Feldman L, Lapin B, Busch RM, Bautista JF. Evaluating subjective cognitive impairment in the adult epilepsy clinic: Effects of depression, number of antiepileptic medications, and seizure frequency. <i>Epilepsy Behav</i>. 2018;81:18-24. doi:10.1016/j.yebeh.2017.10.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/29455082/pubmed" id="29455082" target="_blank">29455082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28732239">
<a name="28732239"></a>Finsterer J, Scorza FA. Effects of antiepileptic drugs on mitochondrial functions, morphology, kinetics, biogenesis, and survival. <i>Epilepsy Res</i>. 2017;136:5-11. doi:10.1016/j.eplepsyres.2017.07.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/28732239/pubmed" id="28732239" target="_blank">28732239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28276060">
<a name="28276060"></a>Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. <i>Epilepsia</i>. 2017;58(4):522-530.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/28276060/pubmed" id="28276060" target="_blank">28276060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24031104">
<a name="24031104"></a>Foroughipour M, Ghandehari K, Khazaei M, Ahmadi F, Shariatinezhad K, Ghandehari K. Randomized clinical trial of intravenous valproate (orifil) and dexamethasone in patients with migraine disorder. <i>Iran J Med Sci</i>. 2013;38(2 suppl):S150-S155.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/24031104/pubmed" id="24031104" target="_blank">24031104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8190572">
<a name="8190572"></a>Freeman JM, Vining EP, Cost S, et al, “Does Carnitine Administration Improve the Symptoms Attributed to Anticonvulsant Medications?: A Double-Blinded, Crossover Study,” <i>Pediatrics</i>, 1994, 93(6 Pt 1):893-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/8190572/pubmed" id="8190572" target="_blank">8190572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24523483">
<a name="24523483"></a>Friedman BW, Garber L, Yoon A, et al. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. <i>Neurology</i>. 2014;82(11):976-983. doi:10.1212/WNL.0000000000000223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/24523483/pubmed" id="24523483" target="_blank">24523483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3126410">
<a name="3126410"></a>Gal P, Oles KS, Gilman JT, et al, "Valproic Acid Efficacy, Toxicity, and Pharmacokinetics in Neonates With Intractable Seizures," <i>Neurology</i>, 1988, 38(3):467-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/3126410/pubmed" id="3126410" target="_blank">3126410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19836623">
<a name="19836623"></a>Gareri P, Lacava R, Cotroneo A, et al. Valproate-induced delirium in a demented patient. <i>Arch Gerontol Geriatr</i>. 2009;(49 suppl 1):113-118. doi:10.1016/j.archger.2009.09.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19836623/pubmed" id="19836623" target="_blank">19836623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18794645">
<a name="18794645"></a>Gau SS, Chao PF, Lin YJ, Chang CJ, Gau CS. The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study. <i>J Clin Psychopharmacol</i>. 2008;28(5):509-517. doi:10.1097/JCP.0b013e3181845610<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/18794645/pubmed" id="18794645" target="_blank">18794645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16787750">
<a name="16787750"></a>Gerstner T, Buesing D, Longin E, et al. Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children. <i>Seizure</i>. 2006;15(6):443-448. doi:10.1016/j.seizure.2006.05.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/16787750/pubmed" id="16787750" target="_blank">16787750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18162014">
<a name="18162014"></a>Ghaemi SN, Gilmer WS, Goldberg JF, et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study.<i> J Clin Psychiatry</i>. 2007;68(12):1840-1844.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/18162014/pubmed" id="18162014" target="_blank">18162014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24524454">
<a name="24524454"></a>Glass HC. Neonatal seizures: advances in mechanisms and management. <i>Clin Perinatol</i>. 2014;41(1):177-190.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/24524454/pubmed" id="24524454" target="_blank">24524454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28558955">
<a name="28558955"></a>Glass HC, Shellhaas RA, Tsuchida TN, et al. Seizures in preterm neonates: a multicenter observational cohort study. <i>Pediatr Neurol</i>. 2017;72:19-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/28558955/pubmed" id="28558955" target="_blank">28558955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16886973">
<a name="16886973"></a>Glauser T, Ben-Menachem E, Bourgeois B, et al, "ILAE Treatment Guidelines: Evidence-Based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes," <i>Epilepsia</i>, 2006, 47(7):1094-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/16886973/pubmed" id="16886973" target="_blank">16886973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26900382">
<a name="26900382"></a>Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. <i>Epilepsy Curr</i>. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/26900382/pubmed" id="26900382" target="_blank">26900382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22689735">
<a name="22689735"></a>Go CY, Mackay MT, Weiss SK, et al, "Evidence-Based Guideline Update: Medical Treatment of Infantile Spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society," <i>Neurology</i>, 2012, 78(24):1974-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/22689735/pubmed" id="22689735" target="_blank">22689735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26979387">
<a name="26979387"></a>Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. <i>J Psychopharmacol</i>. 2016;30(6):495-553. doi: 10.1177/0269881116636545.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/26979387/pubmed" id="26979387" target="_blank">26979387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3334021">
<a name="3334021"></a>Graves NM, Kriel RL. Rectal Administration of Antiepileptic Drugs in Children. <i>Pediatr Neurol.</i> 1987;3(6):321-326.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/3334021/pubmed" id="3334021" target="_blank">3334021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27428884">
<a name="27428884"></a>Greenberg RG, Melloni C, Wu H, et al. Therapeutic index estimation of antiepileptic drugs: a systematic literature review approach. <i>Clin Neuropharmacol</i>. 2016;39(5):232-240. doi:10.1097/WNF.0000000000000172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/27428884/pubmed" id="27428884" target="_blank">27428884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23480132">
<a name="23480132"></a>Grunze H, Vieta E, Goodwin GM, et al; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. <i>World J Biol Psychiatry</i>. 2013;14(3):154-219. doi: 10.3109/15622975.2013.770551.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/23480132/pubmed" id="23480132" target="_blank">23480132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29098925">
<a name="29098925"></a>Grunze H, Vieta E, Goodwin GM, et al; Members of the WFSBP Task Force on Bipolar Affective Disorders working on this topic. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder. <i>World J Biol Psychiatry</i>. 2018;19(1):2-58. doi: 10.1080/15622975.2017.1384850.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/29098925/pubmed" id="29098925" target="_blank">29098925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-350249">
<a name="350249"></a>Gugler R, Mueller G. Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease. <i>Br J Clin Pharmacol</i>. 1978;5(5):441-446. doi:10.1111/j.1365-2125.1978.tb01652.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/350249/pubmed" id="350249" target="_blank">350249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28747841">
<a name="28747841"></a>Güler S, Işık İ, İşcan A. Onychomadesis: A rare adverse effect in early-period valproic acid therapy. <i>Turk Pediatri Ars</i>. 2017;52(2):98-100. doi:10.5152/TurkPediatriArs.2015.2630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/28747841/pubmed" id="28747841" target="_blank">28747841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18174091">
<a name="18174091"></a>Gunner KB, Smith HD, Ferguson LE. Practice guideline for diagnosis and management of migraine headaches in children and adolescents: part two.<i> Pediatr Health Care</i>. 2008;22(1):52-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/18174091/pubmed" id="18174091" target="_blank">18174091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30931853">
<a name="30931853"></a>Guo HL, Jing X, Sun JY, et al. Valproic acid and the liver injury in patients with epilepsy: an update. <i>Curr Pharm Des</i>. 2019;25(3):343-351. doi:10.2174/1381612825666190329145428<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/30931853/pubmed" id="30931853" target="_blank">30931853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32117699">
<a name="32117699"></a>Gupta T. Valproate-induced drug rash eosinophilia with systemic symptoms syndrome: an unknown hepatotoxicity. <i>Euroasian J Hepatogastroenterol</i>. 2019;9(2):102-103. doi:10.5005/jp-journals-10018-1298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/32117699/pubmed" id="32117699" target="_blank">32117699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12784116">
<a name="12784116"></a>Gyulai L, Bowden CL, McElroy SL, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. <i>Neuropsychopharmacology</i>. 2003;28(7):1374-1382.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/12784116/pubmed" id="12784116" target="_blank">12784116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19398681">
<a name="19398681"></a>Harden CL, Meador KJ, Pennell PB, et al. Practice Parameter Update: Management Issues for Women With Epilepsy-Focus on Pregnancy (an Evidence-Based Review): Teratogenesis and Perinatal Outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology.</i> 2009a;73(2):133-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19398681/pubmed" id="19398681" target="_blank">19398681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19398680">
<a name="19398680"></a>Harden CL, Pennell PB, Koppel BS, et al. Practice Parameter Update Management Issues for Women With Epilepsy-Focus on Pregnancy (an Evidence-Based Review): Vitamin K, Folic Acid, Blood Levels, and Breastfeeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology.</i> 2009b;73(2):142-149.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19398680/pubmed" id="19398680" target="_blank">19398680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27581850">
<a name="27581850"></a>Harris ML, Malloy KM, Lawson SN, Rose RS, Buss WF, Mietzsch U. Standardized treatment of neonatal status epilepticus improves outcome. <i>J Child Neurol</i>. 2016;31(14):1546-1554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/27581850/pubmed" id="27581850" target="_blank">27581850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15040495">
<a name="15040495"></a>Hashim N, Bandara D, Tan E, Ilchyshyn A. Early cyclosporine treatment of incipient toxic epidermal necrolysis induced by concomitant use of lamotrigine and sodium valproate. <i>Acta Derm Venereol</i>. 2004;84(1):90-91. doi:10.1080/00015550310005906<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/15040495/pubmed" id="15040495" target="_blank">15040495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2497768">
<a name="2497768"></a>Herrick AL, McColl KE, Moore MR, Brodie MJ, Adamson AR, Goldberg A. Acute intermittent porphyria in two patients on anticonvulsant therapy and with normal erythrocyte porphobilinogen deaminase activity. <i>Br J Clin Pharmacol</i>. 1989;27(4):491-497. doi:10.1111/j.1365-2125.1989.tb05398.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/2497768/pubmed" id="2497768" target="_blank">2497768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19496806">
<a name="19496806"></a>Hesdorffer DC, Kanner AM. The FDA alert on suicidality and antiepileptic drugs: Fire or false alarm? <i>Epilepsia</i>. 2009;50(5):978-986. doi:10.1111/j.1528-1167.2009.02012.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19496806/pubmed" id="19496806" target="_blank">19496806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hilmas.2000">
<a name="Hilmas.2000"></a>Hilmas E, Lee CK. Valproic acid-related Reye's-like syndrome. <i>The Journal of Pediatric Pharmacy Practice.</i> 2000;5(3):149-155.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10665626">
<a name="10665626"></a>Hirschfeld RM, Allen MH, McEvoy JP, Keck PE Jr, Russell JM. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. <i>J Clin Psychiatry</i>. 1999;60(12):815-818.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/10665626/pubmed" id="10665626" target="_blank">10665626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12894087">
<a name="12894087"></a>Huang YL, Hong HS, Wang ZW, Kuo TT. Fatal sodium valproate-induced hypersensitivity syndrome with lichenoid dermatitis and fulminant hepatitis. <i>J Am Acad Dermatol</i>. 2003;49(2):316-319. doi:10.1067/s0190-9622(03)00748-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/12894087/pubmed" id="12894087" target="_blank">12894087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31783774">
<a name="31783774"></a>Huang W, Ren X, Shen F, Xing B. Sodium valproate induced acute pancreatitis in a bipolar disorder patient: a case report. <i>BMC Pharmacol Toxicol</i>. 2019;20(1):71. doi:10.1186/s40360-019-0373-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/31783774/pubmed" id="31783774" target="_blank">31783774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16970741">
<a name="16970741"></a>Israni RK, Kasbekar N, Haynes K, Berns JS. Use of antiepileptic drugs in patients with kidney disease. <i>Semin Dial</i>. 2006;19(5):408-416. doi:10.1111/j.1525-139X.2006.00195.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/16970741/pubmed" id="16970741" target="_blank">16970741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jirsch.2020">
<a name="Jirsch.2020"></a>Jirsch J, Hirsch LJ. Nonconvulsive status epilepticus: Classification, clinical features, and diagnosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 18, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16448626">
<a name="16448626"></a>Joffe H, Cohen LS, Suppes T, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. <i>Biol Psychiatry</i>. 2006;59(11):1078-1086. doi:10.1016/j.biopsych.2005.10.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/16448626/pubmed" id="16448626" target="_blank">16448626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29453075">
<a name="29453075"></a>Johannessen Landmark C, Farmen AH, Burns ML, et al. Pharmacokinetic variability of valproate during pregnancy - Implications for the use of therapeutic drug monitoring. <i>Epilepsy Res</i>. 2018;141:31-37. doi: 10.1016/j.eplepsyres.2018.02.004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/29453075/pubmed" id="29453075" target="_blank">29453075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31035102">
<a name="31035102"></a>Kacirova I, Grundmann M, Brozmanova H. Valproic acid concentrations in nursing mothers, mature milk, and breastfed infants in monotherapy and combination therapy. <i>Epilepsy Behav</i>. 2019;95:112-116. doi: 10.1016/j.yebeh.2019.04.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/31035102/pubmed" id="31035102" target="_blank">31035102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30386073">
<a name="30386073"></a>Kakunje A, Prabhu A, Sindhu Priya ES, et al. Valproate: It's effects on hair. <i>Int J Trichology</i>. 2018;10(4):150-153. doi:10.4103/ijt.ijt_10_18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/30386073/pubmed" id="30386073" target="_blank">30386073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2118241">
<a name="2118241"></a>Kandrotas RJ, Love JM, Gal P, Oles KS. The effect of hemodialysis and hemoperfusion on serum valproic acid concentration. <i>Neurology</i>. 1990;40(9):1456-1458. doi:10.1212/wnl.40.9.1456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/2118241/pubmed" id="2118241" target="_blank">2118241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31845587">
<a name="31845587"></a>Kang MG, Qian H, Keramatian K, et al. Lithium vs valproate in the maintenance treatment of bipolar I disorder: a post- hoc analysis of a randomized double-blind placebo-controlled trial. <i>Aust N Z J Psychiatry</i>. 2020;54(3):298-307. doi:10.1177/0004867419894067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/31845587/pubmed" id="31845587" target="_blank">31845587</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kernitsky L, O'Hara KA, Jiang P, Pellock JM. Extended-release divalproex in child and adolescent outpatients with epilepsy. <i>Epilepsia</i>. 2005;46(3):440-443. doi:10.1111/j.0013-9580.2005.39804.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/15730542/pubmed" id="15730542" target="_blank">15730542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25309611">
<a name="25309611"></a>Kim SJ, Jhun BW, Lee JE, Kim K, Choi HY. A case of drug-induced interstitial pneumonitis caused by valproic acid for the treatment of seizure disorders. <i>Tuberc Respir Dis (Seoul)</i>. 2014;77(3):145-148. doi:10.4046/trd.2014.77.3.145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/25309611/pubmed" id="25309611" target="_blank">25309611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9137847">
<a name="9137847"></a>Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study [published correction appears in: <i>Cephalalgia</i> 1997;17(7):798]. <i>Cephalalgia</i>. 1997;17(2):103-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/9137847/pubmed" id="9137847" target="_blank">9137847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-346355">
<a name="346355"></a>Klotz U, Rapp T, Müller WA. Disposition of valproic acid in patients with liver disease. <i>Eur J Clin Pharmacol</i>. 1978;13(1):55-60. doi:10.1007/BF00606683<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/346355/pubmed" id="346355" target="_blank">346355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26823359">
<a name="26823359"></a>Knights M, Thekkekkara T, Morris A, Finlay E. Sodium valproate-induced Fanconi type proximal renal tubular acidosis. <i>BMJ Case Rep</i>. 2016;2016:bcr2015213418. doi:10.1136/bcr-2015-213418<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/26823359/pubmed" id="26823359" target="_blank">26823359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10612272">
<a name="10612272"></a>Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. <i>Drug Saf</i>. 1999;21(6):489-501. doi:10.2165/00002018-199921060-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/10612272/pubmed" id="10612272" target="_blank">10612272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6766529">
<a name="6766529"></a>Koch-Weser J, Browne TR. Drug therapy: valproic acid. <i>N Engl J Med</i>. 1980;302(12):661-666.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/6766529/pubmed" id="6766529" target="_blank">6766529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25209632">
<a name="25209632"></a>Kwan Z, Che Ismail RB, Wong SM, Tan LL, Robinson S, Lim KS. Sodium valproate-aggravated psoriasiform eruption. <i>Int J Dermatol</i>. 2014;53(10):e477-e479. doi:10.1111/ijd.12579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/25209632/pubmed" id="25209632" target="_blank">25209632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al; Danish Psychiatric Society.; Danish Society of Obstetrics and Gynecology.; Danish Paediatric Society.; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22706422">
<a name="22706422"></a>Lasić D, Ivanišević R, Uglešić B, Cvitanović MZ, Glučina D, Hlevnjak I. Valproate-acid-induced cutaneous leukocytoclastic vasculitis. <i>Psychiatr Danub</i>. 2012;24(2):215-218.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/22706422/pubmed" id="22706422" target="_blank">22706422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23190215">
<a name="23190215"></a>Leppik IE, Hovinga CA. Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations. <i>Epilepsia</i>. 2013;54(1):28-35. doi:10.1111/epi.12043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/23190215/pubmed" id="23190215" target="_blank">23190215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28411969">
<a name="28411969"></a>Lewis C, Tesar GE, Dale R. Valproate-induced hyperammonemic encephalopathy in general hospital patients with one or more psychiatric disorders. <i>Psychosomatics</i>. 2017;58(4):415-420. doi:10.1016/j.psym.2017.02.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/28411969/pubmed" id="28411969" target="_blank">28411969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15623677">
<a name="15623677"></a>Lewis D, Ashwal S, Hershey A, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society.<i> Neurology</i>. 2004;63(12):2215-2224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/15623677/pubmed" id="15623677" target="_blank">15623677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19280426">
<a name="19280426"></a>Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. <i>Clin Toxicol (Phila)</i>. 2009;47(2):101-111. doi:10.1080/15563650902752376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19280426/pubmed" id="19280426" target="_blank">19280426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17319914">
<a name="17319914"></a>Limdi NA, Knowlton RK, Cofield SS, et al. Safety of rapid intravenous loading of valproate. <i>Epilepsia.</i> 2007;48(3):478-483.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/17319914/pubmed" id="17319914" target="_blank">17319914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36040614">
<a name="36040614"></a>Lin K, Cao VFS, Au C, Dahri K. Clinical pharmacokinetic monitoring of free valproic acid levels: a systematic review. <i>Clin Pharmacokinet</i>. 2022;61(10):1345-1363. doi:10.1007/s40262-022-01171-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/36040614/pubmed" id="36040614" target="_blank">36040614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23797677">
<a name="23797677"></a>Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. <i>Cochrane Database Syst Rev</i>. 2013;(6):CD010611. doi: 10.1002/14651858.CD010611.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/23797677/pubmed" id="23797677" target="_blank">23797677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37868026">
<a name="37868026"></a>Liu JT, Brown CS, Mara KC, et al. Derivation and validation of a new equation for estimating free valproate concentration in critically ill adult patients. <i>Crit Care Explor</i>. 2023;5(10):e0987. doi:10.1097/CCE.0000000000000987<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/37868026/pubmed" id="37868026" target="_blank">37868026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27587068">
<a name="27587068"></a>Mahmoud SH. Antiepileptic drug removal by continuous renal replacement therapy: a review of the literature. <i>Clin Drug Investig</i>. 2017;37(1):7-23. doi:10.1007/s40261-016-0457-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/27587068/pubmed" id="27587068" target="_blank">27587068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22326977">
<a name="22326977"></a>Malamiri RA, Ghaempanah M, Khosroshahi N, Nikkhah A, Bavarian B, Ashrafi MR. Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. <i>Eur J Paediatr Neurol</i>. 2012;16(5):536-541.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/22326977/pubmed" id="22326977" target="_blank">22326977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18986457">
<a name="18986457"></a>Mansur AT, Pekcan Yaşar S, Göktay F. Anticonvulsant hypersensitivity syndrome: clinical and laboratory features. <i>Int J Dermatol</i>. 2008;47(11):1184-1189. doi:10.1111/j.1365-4632.2008.03827.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/18986457/pubmed" id="18986457" target="_blank">18986457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16453247">
<a name="16453247"></a>Masmoudi K, Gras-Champel V, Masson H, Andréjak M. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. <i>Pharmacopsychiatry.</i> 2006;39(1):9-12. doi:10.1055/s-2006-931471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/16453247/pubmed" id="16453247" target="_blank">16453247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25793707">
<a name="25793707"></a>Mazaheri S, Poorolajal J, Hosseinzadeh A, Fazlian MM. Effect of intravenous sodium valproate vs dexamethasone on acute migraine headache: a double blind randomized clinical trial. <i>PLoS One</i>. 2015;10(3):e0120229. doi:10.1371/journal.pone.0120229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/25793707/pubmed" id="25793707" target="_blank">25793707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17888516">
<a name="17888516"></a>McElroy SL, Bowden CL, Collins MA, Wozniak PJ, Keck PE Jr, Calabrese JR. Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder. <i>J Affect Disord</i>. 2008;107(1-3):127-133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/17888516/pubmed" id="17888516" target="_blank">17888516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1673736">
<a name="1673736"></a>Medical Research Council Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patients in remission. <i>Lancet</i>. 1991;337(8751):1175-1180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/1673736/pubmed" id="1673736" target="_blank">1673736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17940245">
<a name="17940245"></a>Mehta V, Singhi P, Singhi S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. <i>J Child Neurol</i>. 2007;22(10):1191-1197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/17940245/pubmed" id="17940245" target="_blank">17940245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16722966">
<a name="16722966"></a>Meierkord H, Boon P, Engelsen B, et al, "EFNS Guideline on the Management of Status Epilepticus," <i>Eur J Neurol</i>, 2006, 13(5):445-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/16722966/pubmed" id="16722966" target="_blank">16722966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21167499">
<a name="21167499"></a>Mindikoglu AL, King D, Magder LS, Ozolek JA, Mazariegos GV, Shneider BL. Valproic acid-associated acute liver failure in children: case report and analysis of liver transplantation outcomes in the United States. <i>J Pediatr</i>. 2011;158(5):802-807. doi:10.1016/j.jpeds.2010.10.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/21167499/pubmed" id="21167499" target="_blank">21167499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16864836">
<a name="16864836"></a>Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. <i>Neurology.</i> 2006;67(2):340-342.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/16864836/pubmed" id="16864836" target="_blank">16864836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18756476">
<a name="18756476"></a>Morrell MJ, Hayes FJ, Sluss PM, et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. <i>Ann Neurol</i>. 2008;64(2):200-211. doi:10.1002/ana.21411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/18756476/pubmed" id="18756476" target="_blank">18756476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22994856">
<a name="22994856"></a>Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. <i>Epilepsia</i>. 2013;54(1):199-203. doi:10.1111/j.1528-1167.2012.03688.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/22994856/pubmed" id="22994856" target="_blank">22994856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25261261">
<a name="25261261"></a>Muralidharan K, Kozicky JM, Bücker J, Silveira LE, Torres IJ, Yatham LN. Are cognitive deficits similar in remitted early bipolar I disorder patients treated with lithium or valproate? Data from the STOP-EM study. <i>Eur Neuropsychopharmacol</i>. 2015;25(2):223-230. doi:10.1016/j.euroneuro.2014.09.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/25261261/pubmed" id="25261261" target="_blank">25261261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8345435">
<a name="8345435"></a>Murphy JV, Groover RV and Hodge C, “Hepatotoxic Effects in a Child Receiving Valproate and Carnitine,” <i>J Pediatr</i>, 1993, 123(2):318-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/8345435/pubmed" id="8345435" target="_blank">8345435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20816041">
<a name="20816041"></a>Muzina DJ, Gao K, Kemp DE, et al. Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial. <i>J Clin Psychiatry. </i>2011;72(6):813-819. doi: 10.4088/JCP.09m05570gre.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/20816041/pubmed" id="20816041" target="_blank">20816041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3918588">
<a name="3918588"></a>Nasrallah HA, Dunner FJ, McCalley-Whitters M. A placebo-controlled trial of valproate in tardive dyskinesia. <i>Biol Psychiatry</i>. 1985;20(2):205-208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/3918588/pubmed" id="3918588" target="_blank">3918588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18031547">
<a name="18031547"></a>Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: A prospective monotherapy study. <i>Epilepsia</i>. 2008;49(3):438-445.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/18031547/pubmed" id="18031547" target="_blank">18031547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: Diagnosis and management (CG183). Published September 3, 2014. Updated November 2018. https://www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2018">
<a name="NICE.2018"></a>National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers. NICE guideline 97. https://www.nice.org.uk/guidance/ng97/evidence/full-guideline-pdf-4852695709. Published June 2018. Accessed March 31, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29315457">
<a name="29315457"></a>Ocek L, Tarhan H, Uludağ FI, et al. Evaluation of sex hormones and sperm parameters in male epileptic patients. <i>Acta Neurol Scand</i>. 2018;137(4):409-416. doi:10.1111/ane.12892<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/29315457/pubmed" id="29315457" target="_blank">29315457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27506102">
<a name="27506102"></a>Okanović M, Zivanović O. Valproate, bipolar disorder and polycystic ovarian syndrome. <i>Med Pregl</i>. 2016;69(3-4):121-126. doi:10.2298/mpns1604121o<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/27506102/pubmed" id="27506102" target="_blank">27506102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29679355">
<a name="29679355"></a>Ono H. Sodium valproate-induced Fanconi syndrome in two severely disabled patients receiving carnitine supplementation. <i>Clin Exp Nephrol</i>. 2019;23(1):148-149. doi:10.1007/s10157-018-1581-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/29679355/pubmed" id="29679355" target="_blank">29679355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6407847">
<a name="6407847"></a>Orr JM, Farrell K, Abbott FS, Ferguson S, Godolphin WJ. The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child. <i>Eur J Clin Pharmacol</i>. 1983;24(3):387-390. doi:10.1007/BF00610060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/6407847/pubmed" id="6407847" target="_blank">6407847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17881258">
<a name="17881258"></a>Ozaydin E, Yükselgüngör H, Köse G. Acute hemorrhagic pancreatitis due to the use of valproic acid in a child. <i>Eur J Paediatr Neurol</i>. 2008;12(2):141-143. doi:10.1016/j.ejpn.2007.07.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/17881258/pubmed" id="17881258" target="_blank">17881258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16772762">
<a name="16772762"></a>Panomvana Na Ayudhya D, Suwanmanee J, Visudtibhan A. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children. <i>Am J Ther</i>. 2006;13(3):211-217. doi:10.1097/01.mjt.0000155113.89092.58<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/16772762/pubmed" id="16772762" target="_blank">16772762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7574471">
<a name="7574471"></a>Papazian O, Cañizales E, Alfonso I, Archila R, Duchowny M, Aicardi J. Reversible dementia and apparent brain atrophy during valproate therapy.<i> Ann Neurol</i>. 1995;38(4):687-91. doi:10.1002/ana.410380423<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/7574471/pubmed" id="7574471" target="_blank">7574471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29957667">
<a name="29957667"></a>Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. <i>Ther Drug Monit</i>. 2018;40(5):526-548. doi: 10.1097/FTD.0000000000000546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/29957667/pubmed" id="29957667" target="_blank">29957667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12423394">
<a name="12423394"></a>Pellock JM, Wilder BJ, Deaton R, Sommerville KW. Acute pancreatitis coincident with valproate use: a critical review. <i>Epilepsia</i>. 2002;43(11):1421-1424. doi:10.1046/j.1528-1157.2002.18502.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/12423394/pubmed" id="12423394" target="_blank">12423394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31421858">
<a name="31421858"></a>Pigoni A, Mandolini GM, Delvecchio G, Bressi C, Soares JC, Brambilla P. A focus on valproate and cognitive deficits in bipolar disorders: A mini-review: Special section on "Translational and Neuroscience Studies in Affective Disorders" Section Editor, Maria Nobile MD, PhD. <i>J Affect Disord</i>. 2020;261:277-281. doi:10.1016/j.jad.2019.08.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/31421858/pubmed" id="31421858" target="_blank">31421858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PinaGarza.2013">
<a name="PinaGarza.2013"></a>Piña-Garza JE. <i>Fenichel's Clinical Pediatric Neurology: A Signs and Symptoms Approach.</i> 7th ed. Philadelphia, PA: Elsevier Saunders; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28391043">
<a name="28391043"></a>Pitetzis DA, Spilioti MG, Yovos JG, Yavropoulou MP. The effect of VPA on bone: From clinical studies to cell cultures-The molecular mechanisms revisited. <i>Seizure</i>. 2017;48:36-43. doi:10.1016/j.seizure.2017.03.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/28391043/pubmed" id="28391043" target="_blank">28391043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-pmsValproicAcid.2020.05">
<a name="pmsValproicAcid.2020.05"></a>pms-Valproic Acid capsules, enteric-coated capsules, oral solution (valproic acid) [product monograph]. Montreal, Quebec, Canada: PharmaScience Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Post.2021">
<a name="Post.2021"></a>Post RM. Bipolar disorder in adults: Choosing maintenance treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20159899">
<a name="20159899"></a>Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. <i>CMAJ</i>. 2010;20;182(7):E269-E276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/20159899/pubmed" id="20159899" target="_blank">20159899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32006792">
<a name="32006792"></a>Quon RJ, Mazanec MT, Schmidt SS, et al. Antiepileptic drug effects on subjective and objective cognition. <i>Epilepsy Behav</i>. 2020;104(Pt A):106906. doi:10.1016/j.yebeh.2020.106906<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/32006792/pubmed" id="32006792" target="_blank">32006792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30873497">
<a name="30873497"></a>Ramachandran A, Visschers RGJ, Duan L, Akakpo JY, Jaeschke H. Mitochondrial dysfunction as a mechanism of drug-induced hepatotoxicity: current understanding and future perspectives. <i>J Clin Transl Res</i>. 2018;4(1):75-100. doi:10.18053/jctres.04.201801.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/30873497/pubmed" id="30873497" target="_blank">30873497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12536052">
<a name="12536052"></a>Ramsay RE, Cantrell D, Collins SD, et al. Safety and tolerance of rapidly infused Depacon. A randomized trial in subjects with epilepsy. <i>Epilepsy Res.</i> 2003;52(3):189-201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/12536052/pubmed" id="12536052" target="_blank">12536052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15898962">
<a name="15898962"></a>Rasgon NL, Altshuler LL, Fairbanks L, et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. <i>Bipolar Disord</i>. 2005;7(3):246-259. doi:10.1111/j.1399-5618.2005.00201.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/15898962/pubmed" id="15898962" target="_blank">15898962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30809807">
<a name="30809807"></a>Rashid M, Kashyap A, Undela K. Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. <i>Int J Dermatol</i>. 2019;58(9):1014-1022. doi:10.1111/ijd.14411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/30809807/pubmed" id="30809807" target="_blank">30809807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10852092">
<a name="10852092"></a>Raskind JY and El-Chaar GM, "The Role of Carnitine Supplementation During Valproic Acid Therapy," <i>Ann Pharmacother</i>, 2000, 34(5):630-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/10852092/pubmed" id="10852092" target="_blank">10852092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16778728">
<a name="16778728"></a>Reed RC and Dutta S. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER? <i>Ther Drug MonitR</i>. 2006;28(3):413-418.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/16778728/pubmed" id="16778728" target="_blank">16778728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15985107">
<a name="15985107"></a>Reiter PD, Nickisch J, Merritt G. Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine. <i>Headache</i>. 2005;45(7):899-903.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/15985107/pubmed" id="15985107" target="_blank">15985107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24964948">
<a name="24964948"></a>Rener-Primec Z, Balkovec V. Valproate-related erythrodermia with reversible encephalopathy: a rare but serious adverse reaction, case report. <i>Acta Dermatovenerol Alp Pannonica Adriat</i>. 2014;23(2):35-38. doi:10.15570/actaapa.2014.9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/24964948/pubmed" id="24964948" target="_blank">24964948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28173638">
<a name="28173638"></a>Riker RR, Gagnon DJ, Hatton C, et al. Valproate protein binding is highly variable in ICU patients and not predicted by total serum concentrations: a case series and literature review. <i>Pharmacotherapy</i>. 2017;37(4):500-508. doi:10.1002/phar.1912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/28173638/pubmed" id="28173638" target="_blank">28173638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14992991">
<a name="14992991"></a>Roepke S, Treudler R, Anghelescu I, Orfanos CE, Tebbe B. Valproic acid and hypersensitivity syndrome. <i>Am J Psychiatry</i>. 2004;161(3):579. doi:10.1176/appi.ajp.161.3.579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/14992991/pubmed" id="14992991" target="_blank">14992991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26252587">
<a name="26252587"></a>Rozen TD. Emergency department and inpatient management of status migrainosus and intractable headache. <i>Continuum (Minneap Minn)</i>. 2015;21(4 headache):1004-1017. doi:10.1212/CON.0000000000000191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/26252587/pubmed" id="26252587" target="_blank">26252587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12221662">
<a name="12221662"></a>Sajatovic M. Treatment of bipolar disorder in older adults. <i>Int J Geriatr </i>
<i>Psychiatry</i>. 2002;17(9):865-873.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/12221662/pubmed" id="12221662" target="_blank">12221662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31546525">
<a name="31546525"></a>Sanoria A, Arora R, Dokania P. Bilateral acute angle closure as presenting feature of drug rash with eosinophilia and systemic symptoms (DRESS). <i>Indian J Ophthalmol</i>. 2019;67(10):1711-1713. doi:10.4103/ijo.IJO_169_19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/31546525/pubmed" id="31546525" target="_blank">31546525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schachter.2023">
<a name="Schachter.2023"></a>Schachter SC. Antiseizure medications: Mechanism of action, pharmacology, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schwedt.2022">
<a name="Schwedt.2022"></a>Schwedt TJ, Garza I. Preventive treatment of episodic migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16774619">
<a name="16774619"></a>Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. <i>Acta Neurol Scand</i>. 2006;114(1):1-7. doi:10.1111/j.1600-0404.2006.00655.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/16774619/pubmed" id="16774619" target="_blank">16774619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12390647">
<a name="12390647"></a>Serdaroglu G, Erhan E, Tekgul H, et al. Sodium valproate prophylaxis in childhood migraine. <i>Headache</i>. 2002;42(8):819-822.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/12390647/pubmed" id="12390647" target="_blank">12390647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31980035">
<a name="31980035"></a>Shah S, Wang R, Vieux U. Valproate-induced hyperammonemic encephalopathy: a case report. <i>J Med Case Rep</i>. 2020;14(1):19. doi:10.1186/s13256-020-2343-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/31980035/pubmed" id="31980035" target="_blank">31980035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shelton.2019">
<a name="Shelton.2019"></a>Shelton RC, Bobo WV. Bipolar major depression in adults: choosing treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25986331">
<a name="25986331"></a>Sheridan D, Sun B, O'Brien P, Hansen M. Intravenous sodium valproate for acute pediatric headache. <i>J Emerg Med</i>. 2015;49(4):541-545.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/25986331/pubmed" id="25986331" target="_blank">25986331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29144993">
<a name="29144993"></a>Sidhu HS, Srinivasa R, Sadhotra A. Evaluate the effects of antiepileptic drugs on reproductive endocrine system in newly diagnosed female epileptic patients receiving either valproate or lamotrigine monotherapy: A prospective study. <i>Epilepsy Res</i>. 2018;139:20-27. doi:10.1016/j.eplepsyres.2017.10.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/29144993/pubmed" id="29144993" target="_blank">29144993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sirven.2023">
<a name="Sirven.2023"></a>Sirven JI. Approach to the discontinuation of antiseizure medications. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed December 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27546759">
<a name="27546759"></a>Smetana KS, Cook AM, Bastin ML, Oyler DR. Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. <i>J Crit Care. </i>2016;36:116-124. doi: 10.1016/j.jcrc.2016.06.023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/27546759/pubmed" id="27546759" target="_blank">27546759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3918159">
<a name="3918159"></a>Snead OC 3rd and Miles MV, "Treatment of Status Epilepticus in Children With Rectal Sodium Valproate," <i>J Pediatr</i>, 1985, 106(2):323-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/3918159/pubmed" id="3918159" target="_blank">3918159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26983583">
<a name="26983583"></a>Solak B, Oztas Kara R, Erdem T. Various simultaneous nail changes due to valproic acid use. <i>Cutan Ocul Toxicol</i>. 2017;36(1):96-97. doi:10.3109/15569527.2016.1156121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/26983583/pubmed" id="26983583" target="_blank">26983583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9202628">
<a name="9202628"></a>Stahl MM, Neiderud J, Vinge E. Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid. <i>J Pediatr</i>. 1997;130(6):1001-1003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/9202628/pubmed" id="9202628" target="_blank">9202628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31113373">
<a name="31113373"></a>Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign Against Headache. <i>J Headache Pain</i>. 2019;20(1):57. doi:10.1186/s10194-018-0899-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/31113373/pubmed" id="31113373" target="_blank">31113373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stovall.2018">
<a name="Stovall.2018"></a>Stovall J. Bipolar disorder in adults: Choosing pharmacotherapy for acute mania and hypomania. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 18, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6412580">
<a name="6412580"></a>Sugimoto T, Nishida N, Yasuhara A, Ono A, Sakane Y, Matsumura T. Reye-like syndrome associated with valproic acid. <i>Brain Dev</i>. 1983;5(3):334-337. doi:10.1016/s0387-7604(83)80029-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/6412580/pubmed" id="6412580" target="_blank">6412580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17381378">
<a name="17381378"></a>Taylor LM, Farzam F, Cook AM, Lewis DA, Baumann RJ, Kuhn RJ. Clinical utility of a continuous intravenous infusion of valproic acid in pediatric patients. <i>Pharmacotherapy</i>. 2007;27(4):519-525.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/17381378/pubmed" id="17381378" target="_blank">17381378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19014751">
<a name="19014751"></a>Tohen M, Vieta E, Goodwin GM, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. <i>J Clin Psychiatry</i>. 2008;69(11):1776-1789.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19014751/pubmed" id="19014751" target="_blank">19014751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26096509">
<a name="26096509"></a>Toker O, Tal Y, Horev L, Shmoeli D, Gilboa T. Valproic acid hypersensitivity and desensitization. <i>Dev Med Child Neurol</i>. 2015;57(11):1076-1078. doi:10.1111/dmcn.12835<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/26096509/pubmed" id="26096509" target="_blank">26096509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32239268">
<a name="32239268"></a>Toledo M, Mostacci B, Bosak M, et al. Expert opinion: use of valproate in girls and women of childbearing potential with epilepsy: recommendations and alternatives based on a review of the literature and clinical experience-a European perspective. <i>J Neurol</i>. 2021;268(8):2735-2748. doi:10.1007/s00415-020-09809-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/32239268/pubmed" id="32239268" target="_blank">32239268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15858222">
<a name="15858222"></a>Tong V, Teng XW, Chang TK, Abbott FS. Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. <i>Toxicol Sci</i>. 2005;86(2):436-443. doi:10.1093/toxsci/kfi185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/15858222/pubmed" id="15858222" target="_blank">15858222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24806973">
<a name="24806973"></a>Trinka E, Höfler J, Zerbs A, Brigo F. Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. <i>CNS Drugs</i>. 2014;28(7):623-639.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/24806973/pubmed" id="24806973" target="_blank">24806973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25192484">
<a name="25192484"></a>Tseng YL, Huang CR, Lin CH, et al. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy. <i>Medicine (Baltimore)</i>. 2014;93(11):e66. doi:10.1097/MD.0000000000000066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/25192484/pubmed" id="25192484" target="_blank">25192484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21316884">
<a name="21316884"></a>Tsuyusaki Y, Shimbo H, Wada T, et al. Paradoxical increase in seizure frequency with valproate in nonketotic hyperglycinemia. <i>Brain Dev</i>. 2012;34(1):72-75. doi:10.1016/j.braindev.2011.01.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/21316884/pubmed" id="21316884" target="_blank">21316884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10851397">
<a name="10851397"></a>Uberall MA, Trollmann R, Wunsiedler U, et al. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. <i>Neurology. </i>2000;54(11):2188-2189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/10851397/pubmed" id="10851397" target="_blank">10851397</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ueshima S, Aiba T, Ishikawa N, et al. Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants. <i>J Clin Pharm Ther</i>. 2009;34(4):415-422. doi:10.1111/j.1365-2710.2009.01022.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19583674/pubmed" id="19583674" target="_blank">19583674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31307585">
<a name="31307585"></a>Uetrecht J. Mechanisms of idiosyncratic drug-induced liver injury. <i>Adv Pharmacol</i>. 2019;85:133-163. doi:10.1016/bs.apha.2018.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/31307585/pubmed" id="31307585" target="_blank">31307585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8403815">
<a name="8403815"></a>Underwood TW, Frye CB. Drug-induced pancreatitis. <i>Clin Pharm</i>. 1993;12(6):440-448.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/8403815/pubmed" id="8403815" target="_blank">8403815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-USHHS.2016">
<a name="USHHS.2016"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PharmAssoc.1">
<a name="PharmAssoc.1"></a>Valproate Sodium oral solution [prescribing information]. Greenville, SC: Pharmaceutical Associates Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PharmAssos.2">
<a name="PharmAssos.2"></a>Valproic Acid oral solution [prescribing information]. Greenville, SC: Pharmaceutical Associates Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22516584">
<a name="22516584"></a>van Zoelen MA, de Graaf M, van Dijk MR, et al. Valproic acid-induced DRESS syndrome with acute liver failure. <i>Neth J Med</i>. 2012;70(3):155.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/22516584/pubmed" id="22516584" target="_blank">22516584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24868521">
<a name="24868521"></a>Vázquez M, Fagiolino P, Maldonado C, et al. Hyperammonemia associated with valproic acid concentrations. <i>Biomed Res Int</i>. 2014;2014:217269. doi:10.1155/2014/217269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/24868521/pubmed" id="24868521" target="_blank">24868521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19682062">
<a name="19682062"></a>Verrotti A, Agostinelli S, Coppola G, Parisi P, Chiarelli F. A 12-month longitudinal study of calcium metabolism and bone turnover during valproate monotherapy. <i>Eur J Neurol</i>. 2010;17(2):232-237. doi:10.1111/j.1468-1331.2009.02773.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/19682062/pubmed" id="19682062" target="_blank">19682062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24619070">
<a name="24619070"></a>Verrotti A, Scaparrotta A, Grosso S, Chiarelli F, Coppola G. Anticonvulsant drugs and hematological disease. <i>Neurol Sci</i>. 2014;35(7):983-993. doi:10.1007/s10072-014-1701-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/24619070/pubmed" id="24619070" target="_blank">24619070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15509233">
<a name="15509233"></a>Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. <i>Epilepsia</i>. 2004;45(11):1330-1337. doi:10.1111/j.0013-9580.2004.18804.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/15509233/pubmed" id="15509233" target="_blank">15509233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28437285">
<a name="28437285"></a>Wallenburg E, Klok B, de Jong K, et al. Monitoring protein-unbound valproic acid serum concentrations in clinical practice. <i>Ther Drug Monit</i>. 2017;39(3):269-272.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/28437285/pubmed" id="28437285" target="_blank">28437285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17015559">
<a name="17015559"></a>Werlin SL, Fish DL. The spectrum of valproic acid-associated pancreatitis. <i>Pediatrics</i>. 2006;118(4):1660-1663. doi:10.1542/peds.2006-1182<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/17015559/pubmed" id="17015559" target="_blank">17015559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2002">
<a name="WHO.2002"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29204346">
<a name="29204346"></a>Wu XT, Hong PW, Suolang DJ, Zhou D, Stefan H. Drug-induced hypersensitivity syndrome caused by valproic acid as a monotherapy for epilepsy: First case report in Asian population. <i>Epilepsy Behav Case Rep</i>. 2017;8:108-110. doi:10.1016/j.ebcr.2017.06.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/29204346/pubmed" id="29204346" target="_blank">29204346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23409971">
<a name="23409971"></a>Yamamoto Y, Takahashi Y, Imai K, et al. Risk factors for hyperammonemia in pediatric patients with epilepsy. <i>Epilepsia</i>. 2013;54(6):983-989. doi:10.1111/epi.12125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/23409971/pubmed" id="23409971" target="_blank">23409971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31707295">
<a name="31707295"></a>Yamamoto Y, Takahashi Y, Imai K, Ohta A, Kagawa Y, Inoue Y. Prevalence and risk factors for hyponatremia in adult epilepsy patients: Large-scale cross-sectional cohort study. <i>Seizure</i>. 2019;73:26-30. doi:10.1016/j.seizure.2019.10.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/31707295/pubmed" id="31707295" target="_blank">31707295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22116946">
<a name="22116946"></a>Yang CY, Dao RL, Lee TJ, et al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. <i>Neurology</i>. 2011;77(23):2025-2033. doi:10.1212/WNL.0b013e31823b478c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/22116946/pubmed" id="22116946" target="_blank">22116946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536616">
<a name="29536616"></a>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disord</i>. 2018;20(2):97-170. doi: 10.1111/bdi.12609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/29536616/pubmed" id="29536616" target="_blank">29536616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25167568">
<a name="25167568"></a>Yeap LL, Lim KS, Lo YL, Bakar MZ, Tan CT. Valproate-induced reversible sensorineural hearing loss: a case report with serial audiometry and pharmacokinetic modelling during a valproate rechallenge. <i>Epileptic Disord</i>. 2014;16(3):375-379. doi:10.1684/epd.2014.0671<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/25167568/pubmed" id="25167568" target="_blank">25167568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10219283">
<a name="10219283"></a>Yerby MS, McCoy GB. Male infertility: possible association with valproate exposure. <i>Epilepsia</i>. 1999;40(4):520-521. doi:10.1111/j.1528-1157.1999.tb00752.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/10219283/pubmed" id="10219283" target="_blank">10219283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11891102">
<a name="11891102"></a>Yoshikawa H, Watanabe T, Abe T. Tubulo-interstitial nephritis caused by sodium valproate. <i>Brain Dev</i>. 2002;24(2):102-105. doi:10.1016/s0387-7604(02)00007-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/11891102/pubmed" id="11891102" target="_blank">11891102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12752474">
<a name="12752474"></a>Yu KT, Mills S, Thompson N, et al. Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. <i>Epilepsia.</i> 2003;44(5):724-726.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/12752474/pubmed" id="12752474" target="_blank">12752474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3149565">
<a name="3149565"></a>Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid--1988. <i>Clin Pharmacokinet</i>. 1988;15(6):367-389. doi:10.2165/00003088-198815060-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/3149565/pubmed" id="3149565" target="_blank">3149565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29494433">
<a name="29494433"></a>Zafar MS, Stewart AM, Toupin DN, Cook AM, Baumann RJ. Continuous intravenous valproate as abortive therapy for pediatric status migrainosus. <i>Neurologist</i>. 2018;23(2):43-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valproate-pediatric-drug-information/abstract-text/29494433/pubmed" id="29494433" target="_blank">29494433</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12873 Version 684.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
